AGENDA

 

APRIL 21-24, 2025
WALTER E. WASHINGTON CONVENTION CENTER, WASHINGTON D.C.

 

APPLY TO SPEAK

BOOK YOUR TICKET

 
 
 
 
 

Washington D.C., 21 - 24 April 2025

Schedule

Create your personal agenda –check the favourite icon

Apr 2110:00
Conference pass

BIODEFENSE

Biodefense Workshop

Protecting public health from biothreats to pandemics.

  • What is the progress on new technologies in medical product development?
  • How our governments are incentivizing (portfolio approach), especially with biotech and industry? What International collaborations are being facilitated?

10:10 – 10:50 Coupled lightening talks: ~10 minutes each

How our governments are incentivizing (portfolio approach), especially with biotech and industry?

10:55 – 11:50 Panel: Collaboration with industry: the solution for a sustainable posture for biodefence and global health security

11:50 – 12:50 Panel: Rapid vaccine development through manufacturing innovation

1:00 - 2:00 break

2:00 – 3:10 Panel: What are the remaining bottlenecks holding us back from achieving the 100 day mission?

3:10 – 4:10 Panel: International pandemic funding – how can we make it accessible globally?

4:10 – 5:00 Recap Panel: What are the drivers between different international governments and how can we harmonize these to strengthen our defense from global biothreats?

Bassam Hallis, Deputy Director, Vaccine Development & Evaluation Centre, UK Health Security Agency
Christian Tientcha Happi, Professor of Molecular Biology and Genomics in the Department of Biological Sciences & Director, ACEGID
Hamilton Bennett, Sr. Director Vaccine Access and Partnerships, Moderna
Cristina Cassetti, Division Deputy Director, NIH/NIAID
Kent Kester, Executive Director, Vaccine Research and Development, CEPI
Kelly Warfield, President, R&D, Sabin Vaccine Institute
Matthew G. Clark, Joint Project Manager, CBRN Medical, JPEO-CBRND
Chandresh Harjivan, Special Assistant to the President, Domestic Preparedness and Response to Biological Threats, Office of Pandemic Preparedness and Response Policy (OPPR), Executive Office of The President (EOP)
Moderator: Praneel Jadav, Manager, Infectious Disease Policy, BIO
Session led by: ati---advanced-technology-international
Session led by: lumacyte
Lakshmi Krishnan, Vice-President, Life Sciences, National Research Council Canada
Moderator: Phil Krause, Advisor, WHO
Hamilton Bennett, Sr. Director Vaccine Access and Partnerships, Moderna
Seth Berkley, Former CEO, Gavi, Senior Advisor,, Pandemic Center at Brown Univertsity
Marion Gruber, Vice President of Public Health and Regulatory Affairs, IAVI
Moderator: SOAZIC ELISE WANG SONNE, Economist, World Bank Group
Santiago Cornejo, Executive Manager, Regional Revolving Funds, PAHO
Taylor Sexton, Executive Director, Medical Countermeasures Coalition, Todd Strategy Group
Room 201
Apr 2110:00
Conference pass

ANTIMICROBIAL RESISTANCE

AMR Workshop
Francesca Micoli, Director GVGH Innovation Academy and Senior Project Leader, GVGH
Xufei Huang, MSU Research Foundation Professor, Chemistry and Biomedical Engineering, Michigan State University
Tim Cooke, CEO, Omniose
Luigi Lay, Lecturer -Department of Chemistry, University of Milan
Usman Nakakana, Senior Program officer vaccine development and impact, Gates Foundation
Michael Kowarik, CSO, LimmaTech Biologics AG
Vega Masignani, Alliance Director, CARB-X
James Wassil, COO, Vaxcyte
Douglas Thomson, Venture Partner, Kineticos Life Sciences
Alexander Schmidt, Head of Vaccine Development, Bill & Melinda Gates Medical Research Institute
Arman Majidulla, Assistant Scientist, Johns Hopkins Bloomberg School of Public Health
Chiang-Yun Chen, Researcher, CHO PHARMA INC.
Seanette Wilson, Senior Programme Manager, Biovac Institute
Lewis Schrager, Senior Leader, TB Impact Area, IAVI
Jamie Minchin Reedy, Infectious Disease Project Manager, USAID
Room 207B
Apr 2110:00
Conference pass

VACCINE TECHNOLOGY

Vaccine Technology (AM)

Senior Representative, Orlance

Senior Representative, Advanced Access Health Initiative

Wolfgang Leitner, Chief, Innate Immunity Section, National Institute of Health - NIAID
Derek O'Hagan, Senior Advisor in R&D, GSK Vaccines
Jay Evans, Chief Scientific and Strategy Officer, Inimmune
Sheetij Dutta, Chief Laboratory of Structural Vaccinology, Biologics Research and Development Branch, Walter Reed Army Insitute of Research
Aurelio Bonavia, Vaccine Development, Bill & Melinda Gates Medical Research Institute
Brian Nunnally, Vice President and Enterprise Head of Quality Control, CSL
Roland Ventura, VFI Senior Advisor for Strategy, Vaccine Formulation Institute
Rocio Honigmann, Chief Executive Officer, Amerstem Inc
Room 202A
Apr 2110:00
Conference pass

Optimizing mAbs for Infectious Diseases

mAbs for Infectious Diseases (AM)
  • Strategies to optimize mAbs for malaria
  • Development of mAbs for unmet needs in global health
  • Computationally restoring the potency of clinical antibodies
  • RSV & COVID passive immunization, prevention
  • Developing Ab therapies that keep pace with rapidly evolving viral threats (COVID + Flu)

  • Taking mAbs to the next level: Recombinant polyclonal antibody therapeutics

  • Commercialisation challenges for mAb products – understanding pathways to recommendation

  • Panel: Computational (vs traditional) methods for developing improved vaccines and therapeutics

  • Panel: Global barriers to access for ID mAbs – from manufacture to delivery

Neville Kisalu, Senior Scientist Cellular Immunology Section, Vaccine Research Center, NIH - National Institute of Allergy and Infectious Diseases
Larry Zeitlin, President, Mapp Biopharmaceutical, Inc.
Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory
Richard Hughes IV, Partner, Epstein, Becker & Green, The George Washington University Law School
Robert Allen, Chief Scientific Officer, Invivyd
Jonathan Heeney, Chief Scientific Officer, DIOSynVax Limited
Tara Prasad, Team Lead, Global Vaccine Access, WHO
Dave Liebowitz, Senior Vice President, Early-Stage Clinical Development, Inovio
Giuseppe Sautto, Assistant Professor, Cleveland Clinic
Fadil Bidmos, UK MRC Senior (Non-Clinical) Fellow, Imperial College London
Antonio DiGiandomenico, Senior Director, AstraZeneca
Room 202B
Apr 2110:00
Conference pass

Alternative Vaccine Targets Workshop

Alternative Vaccine Targets (AM)

  • 10am Workshop leaders opening remarks

    10.10am Clinical development of vaccines for opioid overdose and allergy

    Dr Jay Evans, CSO, InImmune; Director, Center for Translational Medicine, University of Montana

    10.30am Advancing a vaccine targeting C9orf72 ALS to the clinical stage

    Dr Robert van der Put, Director Business Development, Intravacc

    10.50am Adjuvant centric development of overdose preventing vaccines targeting fentanyl

    Dr David Dowling, Assistant Professor of Pediatrics, Harvard Medical School; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital

    Dr. Shon Remich, MD, and CMO, Ovax

    11.10am Development of adjuvanted vaccines for allergy and Alzheimer’s and drug addiction

    Dr Nikolai Petrovsky, Chairman, Vaxine Pty Ltd.

    11:30am The potential impact, feasibility and progress in clinical development of senotherapeutics

    11:50am Presentation TBC

    12:10pm Panel Discussion – Topic TBC What are the unique challenges of getting non-traditional target vaccines to market?

    · Ethics of challenge studies

    · Regulatory challenges

    · Considerations for designing & planning trials

    · Funding

    All workshop speakers

Jay Evans, Chief Scientific and Strategy Officer, Inimmune
Robert van der Put, Director Business Development, Intravacc
Nikolai Petrovsky, Chairman, Vaxine Pty.
David Dowling, Assistant Professor of Pediatrics, Harvard Medical School; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital
Shon Remich, MD, and CMO,, ARMR Sciences
Room 204AB
Apr 2110:00
Conference pass

COMBINATION VACCINES

Combination Vaccines (AM)
Bill Hausdorff, Lead, Meningococcal Vaccine Development and Vaccines Public Health Value Proposition and, PATH, Center for Vaccine Innovation and Access
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Peter Hotez, Professor, Baylor College of Medicine
Francesco Berlanda Scorza, Director GVGH, GSK Vaccines for Global Health (GVGH)
Birgitte Giersing, Team Lead, Vaccine Prioritization, World Health Organization
Tim Hirst, CEO, GPN Vaccines
Peter Dull, Deputy Director, Integrated Clinical Vaccine Development, Vaccine Development, Global Health Division, Gates Foundation
Hanna Nohynek, Chief Physician, National Institute for Health and Welfare
Marion Gruber, Vice President of Public Health and Regulatory Affairs, IAVI
Room 206
Apr 2114:00
Conference pass

DRIVING KOREA’S VACCINE R&D CAPABILITIES TOWARDS REGIONAL AND GLOBAL PUBLIC HEALTH

Korea Vaccine Workshop

This workshop will be split into two sections, starting with Korea’s Efforts to Contribute to Regional and Global Vaccine R&D, followed by International Partnerships for Vaccine Equity. Join this workshop to meet speakers not only from South Korea, but also from other international Asian markets that are driving vaccine R&D and manufacturing capacity.

2:00 Korea’s Efforts to Contribute to Regional and Global Vaccine R&D

Current and planned efforts by Korean government and industry to support regional and global Vaccine R&D and local manufacturing

2:45 – 3:30 Panel Discussion with the Korean government and industry on current and future international partnerships in vaccine R&D and local manufacturing

3:30 – 3:45 comfort break

3:45 International Partnerships for Vaccine Equity

Collaboration between Korean and international partners to support regional and global health through partnership in R&D and establishment of local manufacturing of vaccine in LMICs

4:15 Panel: What does it take to collaborate for impact on global vaccine equity? What are some best practices of effort for vaccine R&D and local manufacturing in LMICs?

Kevin Kee-Jong Hong, Professor, KOREA mRNA VACCINE INITIATIVE (KmVAC)
Hyun Joo Yang, Director, GTH-B(Global Traning Hub for Biomanufacturing)
Hani Kim, Executive Director, RIGHT Foundation
Gyoonhee Han, Professor, K-NIBRT
Minsang (Min) Eom, Marketing Team Leader, LG Chem
Stella Hyesun Jun, Director of BD, QuadMedicine, Inc.
Dal-Hee Min, CTO, Lemonex
Nakorn Premsri, Director, National Vaccine Institute
Seokkyu Kim, Director, EuBiologics Co., Ltd.
Soleh Ayubi, Deputy Chief Executive Officer, Bio Farma
Raman Rao, Chief Executive Officer, Hilleman Laboratories Singapore Pte Ltd
Seanette Wilson, Senior Programme Manager, Biovac Institute
Sushant Sahastrabuddhe, Deputy Director General, International Vaccine Institute
Room 202B
Apr 2114:00
Conference pass

HPV ELIMINATION

HPV Workshop by Merck

Achieving Cervical Cancer Elimination through Prevention: Headwinds and Tailwinds

HPV-related cancers are preventable, yet the most effective evidence-based intervention to prevent and eliminate the disease, vaccination faces escalating opposition and misinformation, and an erosion of public trust, jeopardizing the critical progress toward achieving Cervical Cancer Elimination by 2030. At the same time, recent approvals of new self-sampling technology has the promise to help diagnose illness sooner and prompt early intervention. This session will bring together public health, cancer prevention, immunization, screening, and patient advocacy experts and leaders in the U.S. to discuss strategies for safeguarding HPV-cancer prevention efforts, while exploring policy solutions, breakthrough research, and cross-sector collaboration. Panelists will address the urgent need to protect current progress and accelerate and intensify efforts toward eliminating HPV-related cancers, starting with Cervical Cancer. The session will culminate in an interactive strategy session where participants will develop a Top 10 Essential Actions framework—a consensus-driven roadmap to achieve the goals of Cervical Cancer Elimination.

Session led by: merck
Cathy Peters, Strategic Director, State & Local Campaigns - Access to Care, ACSCAN
Erin Abramsohn, Executive Director, Infectious Disease Prevention Network (IDPN)
Fenan Solomon, Director, Market Access & Payment Policy Diagnostic Solutions and Specimen Management Public Affairs, BD
Moderator: Citseko Staples Miller, Managing Director, Public Affairs, FTI Consulting, Inc.
204B
Apr 2114:00
Conference pass

IVI & WHO iNTS FVVA (Full Value of Vaccine Assessment) Meeting

IVI & WHO iNTS Workshop
Jerome Kim, Director General, IVI
Annelies Wilder-Smith, Team Lead, Department of Immunisation, Vaccines and Biologicals, WHO
Robert Kaminski, Consultant, World Health Organization
Myron (Mike) Levine, Professor, University of Maryland School of Medicine
Hyonjin Jeon, Research Management Consultant, International Vaccine Institute
Tarun Saluja, Head of Clinical Development, International Vaccine Institute
Wilbur Chen, Professor of Medicine, University of Maryland School of Medicine
Jungseok Lee, Head of Policy & Economic Research Department, International Vaccine Institute
Simon Proctor, Assistant Professor, London School of Hygiene and Tropical Medicine
Nicole Revie, Senior Consultant, Shift Health
Room 204C
Apr 2114:00
Conference pass

THE GLOBAL MPOX RESPONSE: Epidemiology, Prevention, and Future Strategies HOSTED BY BAVARIAN NORDIC

MPOX Workshop Hosted by Bavarian Nordic

The Global Mpox Response: Epidemiology, Prevention, and Future Strategies

Part I: Epidemiology & Mpox in Non-Endemic Countries

  • Global Mpox Epidemiology: Trends, Insights and Emerging Challenges
  • The Response to the 2022 Mpox Outbreak in Non-Endemic Countries
  • Panel Discussion: Mpox in NON-Endemic Countries

Part II: Mpox Response in Endemic Countries

  • Strengthening Prevention in Endemic Regions: Lessons From the Ground ​
  • The Role of MVA-BN in Mpox Management: Current Data and Future Directions ​
  • Coordinating the Global Mpox Response Across Different Stakeholders: What Can We Learn From It? ​
  • Panel Discussion

Bernard Hoet, Vice President of Medical Strategy, Bavarian Nordic A/S
Boghuma Titanj, Assistant Professor of Medicine, Division of Infectious Diseases, Emory University - School of Medicine
Hypolite Muhindo Mavako, Professor, Department of Tropical Medicine, University of Kinshasa
Rosamund Lewis, Team lead, High threat pathogens, World Health Organization
204AB
Apr 2114:00
Conference pass

VACCINE DELIVERY

Vaccine Delivery (PM)
Dennis Christensen, Head of Global R&D, Croda
Irnela Bajrovic, VP, Partnerships & Alliances, Jurata Thin Film, Inc.
Edward Kelley, Chief Global Health Officer, ApiJect
Rochelle Chaiken, Chief Medical Officer, VAXXAS
Lisa Purcell, Entrepreneur-In-Residence, Third Rock Ventures, LLC
May Pidding, Director, Microneedle Array Patch Product Management, LTS Lohmann
Dan Mallon, SVP Corporate Development, PharmaJet
Room 202A
Apr 2114:00
Conference pass

GLOBAL HEALTH - PARASITIC & NTD VACCINES

Global Health NTDs (PM)

2.10pm – 3.10pm Parasitic disease vaccine development short talks:

4x 15min presentations

2.10pm Hookworm anaemia and malaria combination vaccine development

Dr Peter Hotez, Co-Director, Texas Children’s Hospital Center for Vaccine Development, Baylor College of Medicine

2.25pm Early development of a vaccine against visceral leishmaniasis * Title TBC

Dr Angamuthu Selvapandiyan, Professor, Department of Molecular Medicine, School of Interdisciplinary Studies and Technology, JAMIA HAMDARD

2.40pm Joint Presentation: A defined molecular vaccine for intestinal schistosomiasis * title TBC

Darrick Carter, CEO, PAI LifesciencesAfzal Siddiqui, Professor, Department of Internal Medicine, Professor (Tenured), Departments of Internal Medicine and Immunology & Molecular Immunology, Texas Tech University Health Sciences Center

2.55pm Development of vaccines for lymphatic filariasis *Title TBC

Dr Ramaswamy Kalyanasundaram, Department Head, Professor of Microbiology and Immunology, University of Illinois College of Medicine

3.10pm Panel: Challenges in establishing correlates of protection and planning trials for NTD vaccines

· What are the difficulties in establishing COP for NTD vaccines

· Planning for ph2-3 trials – how can we innovate in creating pathways and designs?

Darrick Carter, CEO, PAI Lifesciences

Afzal Siddiqui, Professor, Department of Internal Medicine, Professor (Tenured), Departments of Internal Medicine and Immunology & Molecular Immunology, Texas Tech University Health Sciences Center

Dr Ramaswamy Kalyanasundaram, Department Head, Professor of Microbiology and Immunology, University of Illinois College of Medicine

Michael, Senior Director, Principal Consultant DCS/BPE, Cencora

Additional panelists TBC

4.00pm Panel: Moving the needle: alternative pathways to approval for global health vaccines (Parasitic & Neglected Diseases)

· Considering pathways to approval in different scenarios – in-country experiences

o Enabling different technology pathways

o From a local manufacturing perspective

· Moving from science to deployment – other than strong data what do we need to move these vaccines forward?

o Understanding incentives for production, government incentives to buy, individual country policies and regulatory requirements

o How is this challenge further compounded with diseases that are not fatal but have high morbidity burden?

o Case studies – Marburg, Hookworm,

· Improving stringency of regulatory agencies through new frameworks

· Can combinations deal with the issue of high burden but low interest? What would be the complications of combining these types of vaccines?

Dr Maria Elena Bottazzi, Co-Director of Texas Children’s Hospital Center for Vaccine Development, Baylor College of Medicine

Dr Kelly Warfield, President of Global Research, Sabin Vaccine Institute

Javier Guzman, Director of Global Health Policy and Senior Fellow, Center for Global Development

Petro Terblanche, Managing Director, Afrigen

Prof Tuck Seng Wong, Professor, Sheffield University; Director, UKSEA Vax Hub

Dr William Hausdorff, Public Health Value Proposition Lead, PATH

Peter Hotez, Professor, Baylor College of Medicine
Angamuthu Selvapandiyan, Professor, Jamia Hamdard
Ramaswamy Kalyanasundaram, Professor Microbiology and Immunology, University of Illinois
Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
Petro Terblanche, Chief Executive Officer, Afrigen Biologics (Pty) Ltd
Darrick Carter, Chief Executive Officer, PAI Life Sciences Inc.
Afzal Siddiqui, Professor & Chair, Texas Tech University Health Sciences Center
Kelly Warfield, President, R&D, Sabin Vaccine Institute
Javier Guzman, Director, Global Health Policy, Center for Global Development
Tuck Seng Wong, Director, UK-SEA Vax Hub; Professor of Biomanufacturing, University of Sheffield
Bill Hausdorff, Lead, Meningococcal Vaccine Development and Vaccines Public Health Value Proposition and, PATH, Center for Vaccine Innovation and Access
Michael Pfleiderer, Senior Director, Principal Consultant DCS/BPE, Phlexglobal Ltd
Room 209AB
Apr 2116:00
Conference pass

RSV INFANT IMMUNIZATION

RSV by Merck

Maximizing Protection: Enhancing National RSV Infant Immunization Strategies

The completion of two seasons of RSV immunization for infants provides us with an opportunity to reflect on ways to enhance policies, programs, and systems to maximize protection for infants. Successful national implementation of an RSV infant immunization program hinges on a coordinated, multi-faceted approach that includes raising awareness, enhancing provider education, ensuring accessibility, and fostering collaboration across various sectors. While we have made progress, there are opportunities to close remaining gaps. This panel will provide perspectives across policy, patient advocacy, and implementation to identify best practices to drive public health impact with these new strategies even as new preventive options become available.

204B

Create your personal agenda –check the favourite icon

Apr 229:00
Conference pass

Chair's Opening Remarks

Keynotes
Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Keynote Theatre, Hall D
Apr 229:10
Conference pass

Opening Keynote Panel: Addressing global health security concerns

Keynotes
  • Adoption of new pandemic accord
  • Funding & research priorities for medical countermeasures for ID
  • Vaccines increasing role in global health security
  • Vaccine equity as a key strategy to control health emergencies
  • Encouraging global compliance and accountability
  • New preparedness & research frameworks to broaden research focus to viral and bacterial families bolstering capabilities to response to unforeseen ID threats –
  • Experience in response to Mpox public health emergency
Delese Mimi Darko, Chief Executive Officer, Food and Drugs Authority, Ghana
Ana Maria Henao-Restrepo, Co-Lead R&D Blueprint for epidemics, Health Emergencies Programme (WHE),, World Health Organisation
Ahmed Ogwell, Senior Advisor, United Nations Foundation
Moderator: Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Seth Berkley, Former CEO, Gavi, Senior Advisor,, Pandemic Center at Brown Univertsity
Michinari Hamaguchi, Director General, AMED SCARDA
Keynote Theatre, Hall D
Apr 2210:00
Conference pass

Keynote panel: H5N1 influenza – how close are we to a pandemic?

Keynotes
  • What are we doing to plan for spillover and how prevent a pandemic?
  • Monitoring the epidemiology of the H5N1 spread, what is the current risk to humans? **
  • Human and veterinary vaccines, what is our approach and focus?
  • What is our global approach to scaling up and stockpiling?

** Talking points subject to change according to developments

Richard Webby, Director, World Health Organization Collaborating Centre for Studies on the Ecology of Influenza in Animals and Birds, St. Jude Children's Research Hospital
Volker Gerdts, Director and Chief Executive Officer, VIDO
Moderator: Michelle Cortez, Senior Editor / Chief Health Correspondent, Bloomberg News
Jenny Harries, Chief Executive Officer, UK Health Security Agency
Hamilton Bennett, Sr. Director Vaccine Access and Partnerships, Moderna
Rick Bright, Founder, Bright Global Health
Keynote Theatre, Hall D
Apr 2211:40
Conference pass

Keynote Panel: Chikungunya - a growing global burden exacerbated by climate change and globalization

Keynotes
  • Introduction of new vaccines and updating medical practice for Chik control.
  • How should we define outbreaks and how could we identify and predict hotspots?
  • How will we meet the demands of more vaccines as climate change drives the need further?
  • How can data science and digital tools transform climate-sensitive infectious disease modelling and response?
Bernard Hoet, Vice President of Medical Strategy, Bavarian Nordic A/S
Moderator: David Hamer, Professor of Global Health and Medicine, Boston University School of Public Health
Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
Lyle Petersen, Director of the Division of Vector-Borne Diseases, NCEZD, CDC
Gabrielle Breugelmans, Director of Epidemiology and Data Science, CEPI
Keynote Theatre, Hall D
Apr 2211:40
Conference pass

Working Group 1: Prophylactic Enteric Disease Vaccines and AMR

Working Groups

Sponsored by Valneva

Session led by: valneva
Hanneke Schuitemaker, CSO, Valneva Austria GmbH
Room 201
Apr 2211:40
Conference pass

Working Group 10: Sponsored by Pratia

Working Groups

Sponsored by Pratia

Room 203AB
Apr 2211:40
Conference pass

Working Group 11: Challenges in mRNA manufacturing: Choosing the right RNA polymerase. Sponsored by Primrose Bio

Working Groups

Sponsored by Primrose Bio

Session led by: primrose-bio
Room 209C
Apr 2211:40
Conference pass

Working Group 12: Accelerating Nucleic Acid Vaccine Production with Synthetic DNA

Working Groups
Session led by: 4basebio
Heikki Lanckriet, CEO, 4basebio
Patrick Thiaville, VP, 4basebio
Room 204C
Apr 2211:40
Conference pass

Working Group 2: Digital and Decentralized Clinical Solutions for Vaccine Clinical Trials

Working Groups
Session led by: thermo-fisher-scientific
Mario Davinelli, Executive Director, Vaccines, Government and Public Health Services, Thermo Fisher Scientific
Jennifer Urwongse, DCT Strategy & Innovation Director, Thermo Fisher Scientific
Sarah Rosen, Senior Director, Non-Interventional Studies, Thermo Fisher Scientific
Room 202A
Apr 2211:40
Conference pass

Working Group 3: Stronger Together – Value Through Strategic Collaborations

Working Groups
Session led by: fhi-clinical
Stephen Thomas, Director, Upstate Global Health Institute, New York Upstate Medical University
Johann de Bruyn, CEO, TASK Clinical Trials
Lucas Tina, Director and Principal Investigator, Victoria Biomedical Research Institute
Room 209AB
Apr 2211:40
Conference pass

Working Group 4: Title TBC

Working Groups
Apr 2211:40
Conference pass

Working Group 5: Best practices in using serological assays to evaluate immunogenicity for vaccine development

Working Groups
Room 208AB
Apr 2211:40
Conference pass

Working Group 6: Considerations for specialized trials

Working Groups

Sponsored by ICON

Room 202B
Apr 2211:40
Conference pass

Working Group 7: Essential insights from sites: leveraging learnings from Parexel’s vaccine alliance network

Working Groups

This roundtable discussion will focus on best practices developed by Parexel’s site alliance network to optimize patient recruitment and retention, keeping participants at the heart of all we do.

  • Discuss strategies that led to the enrollment of approximately 75,000 participants in three ongoing pivotal Phase III programs, including Parexel's dedicated alliance manager system and quarterly pulse forums
  • Share information about Parexel's experience recruiting and retaining diverse populations, including maternal, infant, pediatric, and elderly populations
  • Highlight the Next Generation Site Scholarship program launched in 2024, designed to support emerging sites through mentoring and dedicated man
Room 207B
Apr 2211:40
Conference pass

Working Group 8: Next-Generation mRNA Developments: Anticipated Tools and Trends in the Next Five Years

Working Groups

Sponsored by Trilink

Room 206
Apr 2211:40
Conference pass

Working Group 9: Cracking the Code: Unraveling ePro Challenges in Vaccine Trials

Working Groups

Sponsored by Syneos Health

Host: Lynlee Burton, Vice President, Project Management, Infectious Diseases and Vaccines, Syneos Health
Room 207A
Apr 2212:25
Conference pass

Keynote panel: The emergence and re-emergence of dengue and its unprecedented worldwide spread

Keynotes
  • Effect of climate change on spread
  • Data on circulating serotypes
  • Introduction of new vaccine in high-risk areas
  • Strengthening surveillance systems in affected countries
  • View on vaccine recommendations
  • Global epidemiology and what increases in Americas have meant to US
Anna Durbin, Professor, Johns Hopkins Bloomberg School of Public Health
Gabriela Paz-Bailey, Chief of the Dengue Branch, CDC
Vianney Tricou, Senior Director, Medical & Scientific Affairs, Takeda Pharmaceuticals International AG
Hanna Nohynek, Chief Physician, National Institute for Health and Welfare
Keynote Theatre, Hall D
Apr 2212:40
Conference pass

Working Group 13: Clinical trial retention and diversity *Title TBC

Working Groups
William Smith, CEO, AMR
Room 203AB
Apr 2212:40
Conference pass

Working Group 14: Title TBC

Working Groups
Session led by: luminex-corporation
Room 201
Apr 2212:40
Conference pass

Working Group 15: Navigating Logistics for PBMC Success

Working Groups
Angela Eichler, Director, Specialty Lab Services, JCCT
Room 202A
Apr 2212:40
Conference pass

Working Group 16: How can an engaged and motivated patient community improve vaccine clinical trials?

Working Groups
Session led by: healthmatch
Room 202B
Apr 2212:40
Conference pass

Working Group 17: New Administration, New Rules: What Does it Mean for the Vaccine Industry? *Title TBC

Working Groups
Richard Hughes IV, Partner, Epstein, Becker & Green, The George Washington University Law School
Will Walters, Attorney, Epstein Becker & Green P.C.
Room 207B
Apr 2212:40
Conference pass

Working Group 18: Participant recruitment in the evolving age of vaccine hesitancy

Working Groups
Session led by: thermo-fisher-scientific
Room 207A
Apr 2213:10
Conference pass

Networking Break

Keynotes

Join us in the exhibition hall (Level 2) for:

1:10 – 2:30 1-2-1 Partnering

2:00 – 2:30 Poster Presentations

Exhibition, Hall D
Apr 2213:30
Conference pass

Start-Up Pitches

Expo Stage

13:30 - Thomas Campi, CEO, Modulant Biosciences

13:35 - Robert Forgey, President & CEO, Iaso Therapeutics

13:40 -Gaurav Byagathvalli, Co-Founder & CEO, Piezo Therapeutics

13:45 - Marty Anderson, COO,Profound Research

13:50 - Sander Wuyts, CEO,ImmuneWatch - 'Find the epitope specificity of your T-cell receptors with machine learning'

13:55 -Sarah Alsuleiman, Associate Research Scientist, Athari Biosciences - 'Rapid Immunity Surveillance: Revolutionizing Global Health Security'

14:00 -Daniel Wilson, COO, Pegasus Biotech Inc.

14:05 -Michael Egan, CEO/CSO, CastleVax - 'CastleVax: Development of Next Generation Mucosal Vaccines for Respiratory Viruses and Pandemic Preparedness'

Thomas Campi, CEO, Modulant Biosciences
Robert Forgey, CEO, Iaso Therapeutics, Inc.
Gaurav Byagathvalli, Co-Founder and CEO, Piezo Therapeutics, Inc.
Sander Wuyts, CEO, ImmuneWatch
Daniel Wilson, COO, Pegasus Biotech Inc.
Michael Egan, CEO/CSO, CastleVax
Exhibition Stage, HALL D
Apr 2214:30
Conference pass

Keynote Address: US goals & priorities for infectious disease research in 2025 and beyond

Keynotes
Jeanne Marrazzo, Director, The National Institute of Allergy and Infectious Diseases NIAID
Keynote Theatre, Hall D
Apr 2214:50
Conference pass

Keynote panel: Prophylactic mAbs – coming of age

Keynotes
  • The evolving role of pre-exposure prophylaxis antibodies in a range of infectious diseases
  • In which settings is it appropriate to use mAbs vs vaccines?
    • LMICs
    • Use in vulnerable populations – immunocompromised groups
  • Other than RSV where can mAbs have the most impact?
  • Use of real world data
Sarah S. Long, Emeritus Chief, Infectious Diseases, St. Christopher’s Hospital for Children; Past member, ACIP, VRBPAC, Professor of Pediatrics, Drexel University College of Medicine
Dr Tonya Villafana, Vice President, Franchise and Medical & Scientific Affairs, AstraZeneca
Macaya Douoguih, Vice President, Therapeutic Area Head, Vaccines Clinical Research, Merck Research Laboratories
Robert Allen, Chief Scientific Officer, Invivyd
Marion Gruber, Director Of Office For Vaccines, FDA
Keynote Theatre, Hall D
Apr 2215:50
Conference pass

Keynote panel: New Shots on the block – the status of the vaccine pipeline in 2025

Keynotes
  • Recent and upcoming approvals
  • Flu, RSV, & COVID combinations in trials, Lyme, CMV, EBV, MenB etc
  • How do maunfacturer's leadership view the vaccine landscape, both from scientific and business perspective?
Annaliesa Anderson, SVP and Head, Vaccine R&D, Pfizer
Francesca Ceddia, Chief Medical Affairs Officer, Moderna
Moderator: Anjalee Khemlani, Senior Reporter, Yahoo! Finance
Macaya Douoguih, Vice President, Therapeutic Area Head, Vaccines Clinical Research, Merck Research Laboratories
Rafik Bekkat-Berkani, Vice President, Global Medical Lead Vaccines, GSK
Sally Mossman, VP, Head of Research Portfolio Strategy, Sanofi Vaccines
Keynote Theatre, Hall D
Apr 2216:50
Conference pass

Keynote panel: Measles eradication goals – are they out of reach?

Keynotes
  • Have we made progress in combatting declining immunization rates?
  • Impact of recent outbreaks – how have different countries been responding to tackle them?
  • Public health, behavior and uptake
  • How much has the anti-vaccine movement spilled over into childhood immunizations?
  • Summary of where we are, how do we look post covid vs pre covid as to how we are on track to eliminate measles?
  • Has the reduction in deaths slowed now with the pandemic and are we bouncing back?
Moderator: Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Peter Hotez, Professor, Baylor College of Medicine
Jenny Harries, Chief Executive Officer, UK Health Security Agency
Seth Berkley, Former CEO, Gavi, Senior Advisor,, Pandemic Center at Brown Univertsity
Natasha Crowcroft, Senior Technical Adviser Measles and Rubella, World Health Organization
Walter Orenstein, Professor Emeritus, Emory School of Medicine, Former Associate Director,, Emory Vaccine Center
Keynote Theatre, Hall D
Apr 2217:40
Conference pass

Chair’s Closing Remarks and Close of Congress Day 1

Keynotes
Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Keynote Theatre, Hall D
Apr 2219:30
Conference pass

Gala Dinner & 16th Annual ViE Awards Ceremony

Keynotes

Winners will be announced during the Gala Dinner!

Ball Room ABC, LEVEL 3

Create your personal agenda –check the favourite icon

Apr 239:00
Conference pass

Chair's Opening Remarks

Cancer Immunotherapy
Maria Karasarides, Former Vice President, Worldwide Medical Oncology, Early Assets & Biomarkers, The Delphina Group
Room 206
Apr 239:00
Conference pass

Chair's Opening Remarks

Emerging & Re-emerging Diseases
Seth Berkley, Former CEO, Gavi, Senior Advisor,, Pandemic Center at Brown Univertsity
Room 202B
Apr 239:00
Conference pass

Chair's Opening Remarks

Clinical Trials
Joan Chambers, Senior Consultant, Tufts Center for the Study of Drug Development, Tufts University Medical School
Room 208AB
Apr 239:00
Conference pass

Chair's Opening Remarks

Veterinary
Simon Graham, Co-Director, IVVN & Group Leader, The Pirbright Institute
Room 204AB
Apr 239:00
Conference pass

Chair's Opening Remarks

Vaccine Safety
Walter Straus, Vice President, Clinical Safety & Risk Management, Moderna Therapeutics
Room 204C
Apr 239:00
Conference pass

Chair's Opening Remarks

Supply & Logistics
Rebecca Gentile, Associate Principal Scientist, Merck
Room 209C
Apr 239:00
Conference pass

Chair's Opening Remarks

Vaccine Access
Jonas Nguh, Immediate Past President, Maryland Public Health Association
Room 203AB
Apr 239:05
Conference pass

Panel: Digitalization, automation and artificial intelligence in vaccine manufacturing

Bioprocessing & Manufacture
Moderator: Inna Ben-Anat, Global Head, Manufacturing 4.0, Sanofi
Moderator: William Falstich, Vice President, Global Supply Chain, Primary Care, Pfizer
Ravi Yalamanchili, SVP Digital, Merck
Irina Ramos, Senior Distinguished Scientist CMC and Innovation, Johnson & Johnson
Room 209AB
Apr 239:10
Conference pass

What is our current understanding on long COVID?

COVID & Beyond
  • Current epidemiology – who has it?
  • Are there new pathophysiological changes?
  • What are the compounding effects on individuals, society and chronic consequences?
Mary Bausch-Jurken, Global Lead Medical Affairs COVID-19, Moderna
Room 207A
Apr 239:10
Conference pass

Sex differences in influenza vaccine responses

Immune Profiling
Sabra L Klein, Professor of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health
Room 207B
Apr 239:10
Conference pass

Panel: Is it worth the risk to develop highly innovative cancer vaccines?

Cancer Immunotherapy
Moderator: Maria Karasarides, Former Vice President, Worldwide Medical Oncology, Early Assets & Biomarkers, The Delphina Group
Scot Ebbinghaus, Vice President and Therapeutic Area Head for Late-Stage Oncology Clinical Development, Merck
Michelle Brown, Vice President, Portfolio Lead, Oncology, Moderna Therapeutics
Claudia-Nanette Gann, Vice President Clinical Development, BioNTech
Ilona Baraniak, Associate Director, Associate Principle Consultant DCS/BPE, Phlexglobal Ltd
Room 206
Apr 239:10
Conference pass

Where are we with adult respiratory combination vaccines? – Title TBC

Influenza & Respiratory
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Room 202A
Apr 239:10
Conference pass

Building innovative partnership models and sustainable models for outbreak pathogens

Emerging & Re-emerging Diseases
Swati Gupta, VP, Head of Emerging Infectious Diseases and Epidemiology, International AIDS Vaccine Initiative
Room 202B
Apr 239:10
Conference pass

Panel: Partnering in Asia – leveraging the region to strengthen the global vaccine ecosystem

Partnerships
  • Opportunities in vaccine research, product development, manufacture and licensure
  • Using PPPs as a model to minimize risk and maximize gains
  • What risks and advantages does international partnerships in Asia provide?
Moderator: Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
Raman Rao, Chief Executive Officer, Hilleman Laboratories Singapore Pte Ltd
Soleh Ayubi, Deputy Chief Executive Officer, Bio Farma
Rachel Park, Director, EuBiologics Co
Bill Cadwallader, VP Business Operations, North America, BioNet-Asia Co., Ltd
Room 201
Apr 239:10
Conference pass

Strategies for improved access to trials * Title TBC

Clinical Trials

Senior Representative, EmVenio

Session led by: emvenio
Room 208AB
Apr 239:10
Conference pass

From Rabies to MPOX: how can we prevent spillover of zoonotic disease at the animal level?

Veterinary
Lindsey Shields, Deputy Director, Epidemic Prepardness and Response, PATH
Ryan Wallace, Lead, Rabies Team, Poxvirus and Rabies Branch, Division of High Consequence Pathogens and Pathology, CDC
Alasdair King, Executive Director, International Veterinary Health, Merck Animal Health
Lisa Hensley, Distinguished Senior Research Scientist Research Lead - Zoonotic and Emerging Disease Research Unit, USDA
Gregorio Torres, Head of Department, World Organisation for Animal Health
Lucas Huntimer, CSO, Genvax Technologies
Room 204AB
Apr 239:10
Conference pass

Considerations for safety monitoring during outbreaks (the mPox experience)

Vaccine Safety
Robert Chen, Scientific Director, BRIGHTON Collaboration
Dale Nordenberg, Digital Transformation Lead, BRIGHTON Collaboration
Room 204C
Apr 239:10
Conference pass

Strategic vaccine stockpiles for regional epidemics of emerging viruses: a geospatial modeling framework

Supply & Logistics
Shweta Bansal, Professor of Biology, Georgetown University
Room 209C
Apr 239:10
Conference pass

Panel: How are we moving towards seamless vaccine access for adults?

Vaccine Access
    li>
  • Creation of Immunity for Adults Program for uninsured adults
  • Adult vaccination trends in the US and how this data may be used by state officials to improve vaccine uptake in communities
  • Exacerbation of misinformation
  • CDC Bridge program ending & expanding to other vaccines?

Moderator: Thomas Acciani, Director, US Vaccine Policy, GSK
Abby Bownas, Manager, AVAC ; Partner, NVG, NVG LLC
Alana Knudson, Director, NORC Walsh Center for Rural Health Analysis
Erin Abramsohn, Executive Director, Infectious Disease Prevention Network (IDPN)
Chrissie Juliano, Executive Director, Big Cities Health Coalition
Room 203AB
Apr 239:25
Conference pass

10 Days from Outbreak Declaration to Vaccination: The Rwanda Marburg Outbreak Response

Supply & Logistics
Amy Finan, Chief Executive Officer, Sabin Vaccine Institute
Room 209C
Apr 239:40
Conference pass

Current efforts towards a pan-corona vaccine

COVID & Beyond
Gordon Joyce, Chief Structural Biology, EIDB Research
Room 207A
Apr 239:40
Conference pass

Profiling protective immune responses to respiratory viruses using multiplexed pseudotype neutralization platforms

Immune Profiling
Nigel Temperton, Professor and Director, University of Kent
Room 207B
Apr 239:40
Conference pass

Combining respiratory vaccines: COVID and Flu – Title TBC

Influenza & Respiratory
Rituparna Das, Therapeutic Area Head, Respiratory Vaccines, Moderna
Room 202A
Apr 239:40
Conference pass

Valneva’s Chikungunya vaccine – key data in support of licensure and plans to confirm effectiveness

Emerging & Re-emerging Diseases

Plans for real-world evidence generation of the world’s first Chikungunya vaccine (licensed via the accelerated approval pathway)

Susanne Eder-Lingelbach, VP Clinical Development, Valneva
Room 202B
Apr 239:40
Conference pass

Early Phase Vaccine Adaptive Design

Clinical Trials
Session led by: thermo-fisher-scientific
Jay Pottala, Associate Biostatistics Director, PPD
Room 208AB
Apr 239:40
Conference pass

Safety considerations during clinical development

Vaccine Safety
Session led by: curevo-vaccine
Room 204C
Apr 239:55
Conference pass

Driving vaccine adjuvants and delivery systems development to secure a sustainable supply

Bioprocessing & Manufacture
Dennis Christensen, Head of Global R&D, Croda
Room 209AB
Apr 239:55
Conference pass

Panel: Mitigating the growing risk of duplicate and professional participants in vaccine clinical trials

Vaccine Safety
    li>
  • What is the impact?

  • Why is this a particular problem in Vaccine trials?

  • What are the trends we are seeing surrounding this issue?

  • How can this risk be mitigated or prevented?

Session led by: verified-clinical-trials
Moderator: Justin Goodarz, Chief Commercial Officer, Verified Clinical Trials
Lynlee Burton, Vice President, Project Management, Infectious Diseases and Vaccines, Syneos Health
Andrew Cwiertniewicz, Sr. Delivery Director, Fortrea
Kerri Weingard, Cofounder, VP & Global COO, Verified Clinical Trials
Nick Spittal, Chief Operations Officer, Velocity Clinical Research
Room 204C
Apr 2310:10
Conference pass

Deciphering memory immune responses from live tissue

Immune Profiling
Donna Farber, Chief, Division of Surgical Sciences and Professor of Microbiology & Immunology, Columbia University
Room 207B
Apr 2310:10
Conference pass

LNP Development for mRNA Cancer Immunotherapy

Cancer Immunotherapy
Ghania Chikh, Senior Director, Vaccine Development, Acuitas Therapeutics, Inc.
Session led by: acuitas-therapeutics,-inc.
Room 206
Apr 2310:10
Conference pass

Influenza and COVID-influenza combination vaccine

Influenza & Respiratory
Tonya Colpitts, AVP, Global Project Head, Vaccines, Sanofi
Room 202A
Apr 2310:10
Conference pass

A Novel Single-Dose, Attenuated Live, Minimally Replicative Mpox Vaccine

Emerging & Re-emerging Diseases
Farooq Nasar, Senior Principal Investigator, Research and Development Center, Tonix Pharma
Room 202B
Apr 2310:10
Conference pass

Who to partner with and how for effective pandemic preparedness

Partnerships

With so many consortium and initiatives that are working towards this, how do we navigate through them in order to make meaningful and impactful progress?

Room 201
Apr 2310:10
Conference pass

From Concept to Clinic: Leveraging Innovative Bioprocessing Technologies for Rapid RNA-Based Therapies Development

Bioprocessing & Manufacture
José Castillo, Chief Executive Officer, Quantoom Biosciences
Michael Lambin, Development Technical Lead Manager, Exothera
Room 209AB
Apr 2310:10
Conference pass

From In Vivo Animal Studies to In Vitro Assay Development and Testing * Title TBC

Clinical Trials

Senior Representative, IQVIA Laboratories

Session led by: iqvia
Room 208AB
Apr 2310:10
Conference pass

The evolving threat from H5 influenza viruses

Veterinary
Richard Webby, Director, World Health Organization Collaborating Centre for Studies on the Ecology of Influenza in Animals and Birds, St. Jude Children's Research Hospital
Room 204AB
Apr 2310:10
Conference pass

Panel: Ensuring equitable vaccine distribution during outbreaks

Supply & Logistics
Nupur Parikh, Policy Officer, Health, The ONE Campaign
Steven Damon, CEO, Micron Biomedical
Ian Hart, Manufacturing Lead, CEPI
Moderator: Vic Suarez, Principal Growth Partner, Blu Zone Bioscience
Monique K Mansoura, Executive Director, Global Health Security & Biotechnology, Mitre
Room 209C
Apr 2310:10
Conference pass

Respiratory Disease Combination Vaccines: Innovations, Challenges, and Forecasting Demand

Vaccine Access
Isaac Uwins, Senior Analyst, Airfinity
Room 203AB
Apr 2310:25
Conference pass

Immucise™ Intradermal Injection System for vaccine administration and its application in cancer treatment

Cancer Immunotherapy
Session led by: terumo
Ryo Tanaka, Senior Research Scientist, Terumo
Room 206
Apr 2311:00
Conference pass

Company Presentations

Expo Stage

11:00am – Senior Representative, Ubrigene

11:10am – "The MEU, Manchester. A Vaccine Case Study"- David Rogers, CEO, Medicines Evaluation Unit and CRO Solutions

David Rogers, CEO, MEU
Exhibition Stage, HALL D
Apr 2311:40
Conference pass

Panel: Do we need a perfectly matching strain in our next COVID vaccines?

COVID & Beyond
  • The epidemiology and efficiency of strain matching thus far
  • Will our new vaccines work better than our old ones for the immune population?
  • Who are our COVID vaccines for and how to we sustain uptake?
  • What are the clinical consequences of imprinting? How do we to measure this, do other platform act differently?
Ruben Rizzi, SVP Global Regulatory Affairs, BioNTech SE
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Darin Edwards, Executive Director, COVID Vaccines Program Leader, Moderna Therapeutics
Moderator: Phil Krause, Advisor, WHO
Dan Barouch, Professor Of Medicine, Harvard Medical School
Room 207A
Apr 2311:40
Conference pass

The identification and validation of conserved T cell Epitope regions in Viral Pathogen Families with Pandemic Potential

Immune Profiling
Alessandro Sette, Professor, La Jolla Institute for Allergy and Immunology
Room 207B
Apr 2311:40
Conference pass

New frontiers in cancer vaccine antigens: AI-driven target discovery for broader therapeutic reach *Title TBC

Cancer Immunotherapy
Stine Friis, Director, Business Development, Evaxion Biotech A/S
Room 206
Apr 2311:40
Conference pass

Advancing Influenza Prevention: Latest Clinical Insights on OVX836, a Broad-spectrum T-Cell Influenza Vaccine

Influenza & Respiratory

Alexandre Le Vert, Chief Executive Officer, Osivax
Room 202A
Apr 2311:40
Conference pass

Navigating Vaccine Trials in Low- and Middle-Income Countries: Challenges and Opportunities

Emerging & Re-emerging Diseases
Jaime E Hernandez, Executive Medical Director, Clinical Development, Syneos Health
Lynlee Burton, Vice President, Project Management, Infectious Diseases and Vaccines, Syneos Health
Room 202B
Apr 2311:40
Conference pass

Accelerator™ Drug Development

Partnerships
Hajir Mokhtari, Director, accelerated drug development solutions, PPD clinical research business, Thermo Fisher Scientific
Julia Oswald, Senior Director, Project Management, PPD clinical research business, Thermo Fisher Scientific
Room 201
Apr 2311:40
Conference pass

Innovative Nucleic Acid Delivery Technologies: Manufacturing Implications for the Future of Vaccine Development

Bioprocessing & Manufacture
Ian Villamagna, Sales Specialist- DNA & RNA Therapeutics, Sartorius
Room 209AB
Apr 2311:40
Conference pass

Navigating challenges in vaccine trials for special populations* Title TBC

Clinical Trials

Senior Representative, ICON Plc

Session led by: icon-plc
Room 208AB
Apr 2311:40
Conference pass

Utilization of RNA vaccines for animal health

Veterinary
John El-Attrache, Director of Scientific Services, CEVA santé Animale
Room 204AB
Apr 2311:40
Conference pass

Using Tree-Based Scan Statistics to Monitor Routine Vaccines for Possible Associations with Guillain-Barré Syndrome in the Vaccine Safety Datalink

Vaccine Safety
Judy Maro, Associate Professor of Population Medicine, Harvard Medical School
Room 204C
Apr 2311:40
Conference pass

Strategies to increase supply of BCG024

Supply & Logistics
Jessica Kogan, Principal Scientist, Regulatory Affairs CMC, Merck And Co Inc
Charles Kline, Associate Vice President, Merck
Room 209C
Apr 2311:40
Conference pass

Evolution of the U.S. vaccines go-to-market model: What it takes to win

Vaccine Access
  • How has the landscape of US GTM models changed post-covid?
  • How can companies ensure future success in a crowded market?
Jennifer Heller, Partner, McKinsey and Company
Jenna Benefield, Associate Partner, McKinsey and Company
Room 203AB
Apr 2311:55
Conference pass

Build biology overnight: Make the DNA you want, when you want it

Cancer Immunotherapy
David Weiss, Director Corporate Development, Telesis Bio -
Room 206
Apr 2311:55
Conference pass

Vaccine Assessment: Serological assays for Viruses and Bacteria

Influenza & Respiratory
Alessandro Manenti, Chief Development Officer, Vismederi
Room 202A
Apr 2312:10
Conference pass

Systems immunology approaches to define age-specific predictors of vaccine immunogenicity

Immune Profiling
Ofer Levy, Director, Precision Vaccines Program, Boston Children's Hospital
Room 207B
Apr 2312:10
Conference pass

Enhancing cell-based vaccine production with new animal-free recombinant proteins

Influenza & Respiratory
Marie-Louise Lunn, Senior Product Manager, Novo Nordisk Pharmatech
Room 202A
Apr 2312:10
Conference pass

Jurata's Role in Combatting Emerging Infectious Threats

Emerging & Re-emerging Diseases
Irnela Bajrovic, VP, Partnerships & Alliances, Jurata Thin Film, Inc.
Room 202B
Apr 2312:10
Conference pass

Panel: Strengthening the market and regulatory access of vaccines in Africa

Partnerships
  • How do we increase local vaccine manufacturing capacity and bolster regulatory systems within African nations?
  • The power of fostering regional collaboration on procurement and market dynamics
  • Building capacity for R&D and implementing and strengthening African vaccine manufacturers
  • The need for targeted initiatives to address vaccine hesitancy
Delese Mimi Darko, Chief Executive Officer, Food and Drugs Authority, Ghana
Petro Terblanche, Chief Executive Officer, Afrigen Biologics (Pty) Ltd
Rajinder Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers Network
Dakshina Reddy, Head of Global Regulatory Strategy and Operations, Bill & Melinda Gates Medical Research Institute
William Ampofo, Chief Executive Officer, National Vaccine Institute
Moderator: Seanette Wilson, Senior Programme Manager, Biovac Institute
Room 201
Apr 2312:10
Conference pass

Innovations in RNA design and manufacturing

Bioprocessing & Manufacture
Kate Broderick, Chief Science and Innovation Officer, Maravai LifeSciences
Room 209AB
Apr 2312:10
Conference pass

Novel Vaccine Delivery Technologies: Clinical and Regulatory Considerations

Clinical Trials
Session led by: allucent
Sugato De, VP, Regulatory Strategy, Head of MedTech, Allucent
Room 208AB
Apr 2312:10
Conference pass

Computationally Optimized Broadly Reactive Antigens (COBRA) as Next Generation Broad-spectrum Vaccine Against Bird Flu

Veterinary
Aemro Kassa, Senior Associate Director, Viral Vaccine Exploration, Boehringer Ingelheim Animal Health
Room 204AB
Apr 2312:10
Conference pass

What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunization to inform vaccine safety

Vaccine Safety
Hazel Clothier, Lead Epidemiologist, Vaccine Safety, Center for Health Analytics, Mudoch Childrens Research Institute
Room 204C
Apr 2312:25
Conference pass

What if your delivery system could improve the effectiveness of your cancer therapeutic?

Cancer Immunotherapy
Session led by: pharmajet
Gregg Wilson, Director of Scientific and Medical Affairs, PharmaJet
Room 206
Apr 2312:25
Conference pass

Development of an inactivated EV D68 vaccine using Vero cell platform technology

Emerging & Re-emerging Diseases
Wouter van den Braak, Business Development Associate, Intravacc
Room 202B
Apr 2312:25
Conference pass

Anti-vaccine rhetoric in legislature

Vaccine Access
Rekha Lakshmanan, Chief Strategy Officer, The Immunization Partnership
Room 203AB
Apr 2312:40
Conference pass

Fireside Chat: Rapidly partnering in business and science – how RRPV is unleashing domestic health innovation

COVID & Beyond

Session led by: ati---advanced-technology-international
Jennifer Alton, President, Pathway Policy Group
Jill Hamaker, Senior Partner and Chief Development Officer, CGCN
Praneel Jadav, Manager, Infectious Disease Policy, BIO
Taylor Sexton, Executive Director, Medical Countermeasures Coalition, Todd Strategy Group
Room 207A
Apr 2312:40
Conference pass

AI-assisted immunogen design

Immune Profiling
Jimmy Gollihar, Head of Antibody Discovery and Accelerated Protein Therapeutics (ADAPT), Houston Methodist Hospital
Room 207B
Apr 2312:40
Conference pass

DNA immunotherapeutics in the treatment of cancers and virally-mediated diseases

Cancer Immunotherapy
Jeffrey Skolnik, Senior Vice President, Clinical Development, Inovio Pharmaceuticals
Room 206
Apr 2312:40
Conference pass

C1 Platform: The Urgent Need for Smarter Biomanufacturing – A Call to Action on Avian Influenza (H5N1) & Future Pandemics

Influenza & Respiratory
Mark Emalfarb, Chief Executive Officer, Dyadic International Inc
Room 202A
Apr 2312:40
Conference pass

The role of VIMKUNYA in the prevention of Chikungunya

Emerging & Re-emerging Diseases
Alejandra Goncalves, Medical Science Liaison, Southeast, Bavarian Nordic
Room 202B
Apr 2312:40
Conference pass

A trailblazing digital approach coupled with PAT-enabled rapid manufacturing from MIT and ReciBioPharm (Case Study No. 1 xRNA)

Bioprocessing & Manufacture
Aaron Cowley, CSO, ReciBioPharm
Room 209AB
Apr 2312:40
Conference pass

Launching & leading successful vaccine studies: the essential role of Parexel’s site alliance network

Clinical Trials

This presentation will highlight how our strong site alliance network accelerates start-up, and streamlines conduct of vaccine trials, leading to fast and efficient study execution.

  • Parexel's Site Alliance Network includes over 350 alliance institutions and 21,000+ site investigators across 27 countries
  • Key benefits for sites include assignment of a dedicated alliance manager and contract lead, as well as one-time negotiation of a master service agreement
  • Key benefits for sponsors include active, early engagement that optimizes participant recruitment and retention while ensuring patient-centered study design
Session led by: parexel
Anne Kasmar, Senior Vice President, Global Therapeutic Head, Infectious Disease and Vaccines, Parexel
Room 208AB
Apr 2312:40
Conference pass

Next Generation DNA vaccines for ‘One Health’ – Title TBC

Veterinary
Thomas Tillett, Chief Executive Officer, MBF Therapeutics
Room 204AB
Apr 2312:40
Conference pass

Integrating SIDIAP Health Database into the ConCEPTION Common Data Model: Advancing Vaccine Safety Studies within the VAC4EU Consortium

Vaccine Safety

This session explores the integration of SIDIAP (Sistema de Información para el Desarrollo de la Investigación en Atención Primaria), a Spanish health database, into the ConCEPTION Common Data Model (CDM). This initiative represents a significant advancement in vaccine safety research within the VAC4EU (Vaccine Monitoring Collaboration for Europe) Consortium. Managed by IDIAP Jordi Gol, SIDIAP contains comprehensive primary care data from over 5.8 million individuals in Catalonia, providing a robust platform for pharmacoepidemiologic investigations. Aligning SIDIAP with the ConCEPTION CDM standardizes its data, enabling interoperable, scalable, and reproducible research across diverse healthcare systems. This alignment enhances the capacity to detect and analyze vaccine-related adverse events effectively.

The presentation will detail the technical steps involved in this transformation, including data mapping, harmonization, validation, and the use of privacy-preserving Extract, Transform, Load (ETL) methodologies. It will also present case studies, such as analyses of adverse events following vaccination, to demonstrate the practical benefits of harmonized data for vaccine safety monitoring. This integration underscores the importance of standardized data models in bridging localized healthcare datasets with global research frameworks, supporting evidence-based public health decision-making, and fostering multinational collaboration in pharmacovigilance and pharmaepidemiology.

José Martín Solórzano González, Scientific Coordinator, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol (IDIAP )
Felipe Villalobos, Scientific Coordinator, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol (IDIAP )
Room 204C
Apr 2312:40
Conference pass

US Government - Domestic Manufacturing

Supply & Logistics
Nicolette Louissaint, Senior Vice President, Policy and Strategic Planning, The Healthcare Distribution Alliance
Room 209C
Apr 2312:45
Conference pass

Analyzing trends in vaccine related bills from 2015-2024

Vaccine Access
Angela Shen, Consultant, University of Pennsylvania
Room 203AB
Apr 2312:55
Conference pass

Precision vaccines for swine health and the SEQUIVITY dashboard

Veterinary
Jeremy Maurer, Associate Director - Insights and Outcomes, Merck Animal Health
Room 204AB
Apr 2313:10
Conference pass

Start-Up Pitches

Expo Stage

13:10 - David Nees, VP of Business Development, eEnzyme LLC - 'Cost Effective Viral Neutralization Assays Using Readily Available Virus-Like-Particles'

13:15 -Steven Gold, CEO, Boost Biopharma - 'Safer Vaccines for a Complex World'

13:20 -Pooja Tiwari, COO, ARNAV Biotech

13:25 - Dr Catherine Sanders, VP of Business Development, Ozette Technologies - 'RevolutionizingSingle Cell Immune Profiling and Computational Analysis with Ozette Technologies'

13:30 -Selçuk Koçhan, Co-Founder, MOBIQU

13:35 - Olli Rundgren, CEO & Founder, Psyon Games

13:40 - Pamela Housh, Senior Director of Business Development, Eyam Health

Pooja Tiwari, COO/Founder, ARNAV Biotech
David Nees, VP Business Development, Eenzyme L.L.C.
Steven Gold, CEO, Boost Biopharma
Selçuk Koçhan, Co-Founder, CEO, MOBIQU
Catherine Sanders, VP, Business Devevlopment, Ozette Technologies
Pamela Housh, Senior Director of Business Development, Eyam Health
Exhibition Stage, HALL D
Apr 2314:40
Conference pass

Intranasal Immunization: Device and Formulation Promises and Challenges

COVID & Beyond

Julie Suman, Vice President, Scientific Affairs, Aptar Pharma
Nektaria Karavas, Business Development Director, Aptar Pharma
Room 207A
Apr 2314:40
Conference pass

Advancing Vaccine Immunomonitoring: High-Parameter Spectral Flow Cytometry for Comprehensive Immune Profiling in Vaccine Clinical Trials

Immune Profiling
Session led by: thermo-fisher-scientific
Kevin Lang, Senior Research Scientist, Laboratory Services Bioanalytical Lab, PPD, part of Thermo Fisher Scientific
Room 207B
Apr 2314:40
Conference pass

Combination checkpoint inhibitor vaccines PD1-Vaxx in Phase 1 trial and preclinical with emphasis on TIGIT + PD1-Vaxx, PDL1-Vaxx and CTLA-4 Vaxx in syngeneic cancer mouse models

Cancer Immunotherapy
Pravin Kaumaya, Professor & Director, Indiana university School of Medicine
Room 206
Apr 2314:40
Conference pass

Raising the Temperature: New Challenge Agents, Febrile Illness, and Vaccine Efficacy Testing

Influenza & Respiratory
Alex Mann, Business Development, hVIVO
Room 202A
Apr 2314:40
Conference pass

Afternoon Chair

Emerging & Re-emerging Diseases
David Weiner, Executive Vice President and Director of Vaccine and Immunotherapy Center, The Wistar Institute
Apr 2314:40
Conference pass

Afternoon Chair

Emerging & Re-emerging Diseases
David Weiner, Executive Vice President and Director of Vaccine and Immunotherapy Center, The Wistar Institute
Apr 2314:40
Conference pass

Assay Development Advancements in Human Metapneumovirus (hMPV) Vaccine Research

Emerging & Re-emerging Diseases
Marta Murreddu, Business Development Manager, Cerba Research
Room 202B
Apr 2314:40
Conference pass

Panel: Where are the international bio-vaccine cluster regions around the world?

Partnerships

What opportunities are available globally and how could you partner with them?

Moderator: Jerome Kim, Director General, IVI
Ritu Banerjee, Assistant Deputy Minister, Office of Life Sciences and Biomanufacturing
Candice Roux, Program Manager: Grants, Innovation and Product Development, South African Medical Research Council
Rino Rappuoli, Scientific Director, Fondazione Biotecnopolo di Siena
Room 201
Apr 2314:40
Conference pass

Transforming Vaccine Development and Manufacturing: Integrating Technology and Accessibility for a Healthier 21st Century

Bioprocessing & Manufacture
Jian (Jason) He, Executive Director, Head of BD and CMC, WuXi Biologics - WuXi XDC
Room 209AB
Apr 2314:40
Conference pass

Maximizing vaccine trial efficiency with eSource technology

Clinical Trials
Mia Castagnero, Director, Business Development, Clinical Research IO (CRIO)
Session led by: clinical-research-io-(crio)
Room 208AB
Apr 2314:40
Conference pass

Unlocking the power of Innate Immunity from honeybees to aquaculture

Veterinary
Erin Strait, Chief Scientific Officer, Dalan Animal Health
Room 204AB
Apr 2314:40
Conference pass

How can we leverage surveillance systems and implement more systematic protocols to better estimate background rates and disease burden for respiratory vaccines? *Title TBC

Vaccine Safety
Kashmira Date, Senior Director, Medical & Scientific Affairs (Pipeline Vaccines), Pfizer
Room 204C
Apr 2314:40
Conference pass

Panel: Mitigating against the continued erosion of public health authorities in the USA

Vaccine Access
Georges Benjamin, Executive Director, American Public Health Association
Richard Hughes IV, Partner, Epstein, Becker & Green, The George Washington University Law School
James Hodge, Jr., J.D., LL.M, Peter Kiewit Foundation Professor of Law, Director, Center for Public Health Law and Policy, Arizona State University
Moderator: Allison Winnike, Director, Western Region, The Network for Public Health Law
Room 203AB
Apr 2314:55
Conference pass

Streptococcus suis Differential pathogenesis

Veterinary
Paul Lawrence, Director of Research and Development, Bimeda
Room 204AB
Apr 2314:55
Conference pass

Expanding Access and Reducing Costs: How Distributed Manufacturing of the BFS Prefilled Drug Delivery Platform Enhances Logistics

Supply & Logistics
Bo Kowalczyk, Chief Commercial Officer, ApiJect
Room 209C
Apr 2315:10
Conference pass

Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination

COVID & Beyond

James Cummings, Chief Medical Officer, Vaxart
Room 207A
Apr 2315:10
Conference pass

Leveraging Digital SPR to Differentiate Vaccine Manufacturing Processes

Immune Profiling
Session led by: nicoya
Thomas Linnekin, Scientist I, SeromYx Systems
Room 207B
Apr 2315:10
Conference pass

Clinical Updates for a novel preventative breast cancer vaccine

Cancer Immunotherapy
Olivera (Olja) Finn, Distinguished Professor, Department of Immunology, University of Pittsburgh
Room 206
Apr 2315:10
Conference pass

Avian Influenza Solutions to Support Assay and Vaccine Development

Influenza & Respiratory
Katy Stein, Virology Scientist, Microbiologics
Room 202A
Apr 2315:10
Conference pass

Successful Scaling of Next-Generation Vaccine Manufacturing from R&D to GMP

Bioprocessing & Manufacture
Hagen Richter, Scientist, Wacker Biotech
Room 209AB
Apr 2315:10
Conference pass

Achieving vaccine research excellence: Key insights for sponsors, CROs, and PIs

Clinical Trials

In the dynamic field of vaccine research, selecting and partnering with high-quality clinical research sites is crucial for success. This presentation will provide a comprehensive roadmap tailored to the unique demands of vaccine studies, detailing the necessary steps to establish, maintain, and evaluate a high-quality clinical research sites. We will delve into the critical factors that ensure successful vaccine trials, including PI engagement, facility requirements, staff training, and quality control measures. Through real-life examples and case studies, attendees will gain actionable insights to advance vaccine research and foster strong, collaborative partnerships.

Session led by: avacare
Cynthia “Cindy” Dukes, Senior Therapeutic Strategy Director, Medical and Site Operations, Avacare
Room 208AB
Apr 2315:10
Conference pass

Panel: Regulating new technologies in animal health

Veterinary
Geetha Srinvas, Director, CVB, USDA
Amy Purse, Biological Regulatory Affairs Advisor, Elanco
Rick Hill, President, IABS
Tiffany Nation, Head of Regulatory Affairs Biologicals, US and Primary Market, Boehringer Ingelheim Animal Health USA Inc
Moderator: Mary Jane McNamee, Dir. of Scientific & Regulatory Affairs, Animal Health Institute
Moderator: Klaus Hellmann, Head of Europe CRO, Argenta
Matthew Lucia, Director, Office of New Animal Drug Evaluation, FDA
Room 204AB
Apr 2315:10
Conference pass

Best practices in safety surveillance for dengue vaccination programs – what questions remain unanswered?

Vaccine Safety
Daniel Salas, Executive Manager, Comprehensive Immunization, PAHO
Room 204C
Apr 2315:10
Conference pass

The Source of Saponin Adjuvants: QS21 - Approved, Available, and Abundant – Title TBC

Supply & Logistics

Senior Representative, Desert King

Room 209C
Apr 2315:25
Conference pass

Scaling new heights: ionizable lipids for vaccine development, GMP manufacturing, and clinical success

COVID & Beyond

Martin Rabel, Global Sales Specialist | Biopharma Services, Cytiva
Room 207A
Apr 2315:25
Conference pass

Impact of PBMC stabilisation reagents on the use of aged blood in FluoroSpot & Flow Cytometric platforms

Immune Profiling
Session led by: revvity
Nisha Gopal, Laboratory Operations Technical Manager, Revvity
Room 207B
Apr 2315:25
Conference pass

Enhancing immunoassay sensitivity and specificity for reliable multi-valent vaccine QC

Influenza & Respiratory
Pernille Elverdal, SrVP, Global RA, Clinical Evidence,Medical affairs, SSI Diagnostica A/S
Room 202A
Apr 2315:25
Conference pass

Panel: Next Generation Mpox Vaccine Development: Gaps and Solutions

Emerging & Re-emerging Diseases
Moderator: Zeil Rosenberg, Executive Vice President, Medical, Tonix Pharmaceuticals
Room 202B
Apr 2315:25
Conference pass

From bench to clinic: the role of Bioanalysis in preclinical and clinical safety of novel vaccines

Bioprocessing & Manufacture
Kedar Purnapatre, Director-Bioanalytical Operations, Aragen Lifesciences Ltd
Room 209AB
Apr 2315:25
Conference pass

A Shelf-stable, Self-applied Microneedle Array Patch for Improved Vaccine Access

Supply & Logistics
Kathryn Kosuda, Chief Scientific Officer, Vaxess Technologies
Room 209C
Apr 2315:30
Conference pass

Interactive Session hosted by the Mercury Project - Cost-effective and scalable interventions that build vaccine demand and support science-based health decision-making

Vaccine Access
    li>
  • Mercury Project Directors present the Mercury Project framework and key findings (~10 mins)
  • Three panelists reflect on 2-3 concrete ideas, based on the results and their organization's mission, they want to take back to their teams after the conference (~5 mins each, 15 total)
  • Audience members take a few minutes to note down their own concrete lessons (to be shared with group post-event) (~5 mins)
  • Audience members share out some of their key notes and how they want to act on them (~10 mins)
  • Closing remarks from Mercury Project Directors (~ 2 mins)

Kathryn Hashey, Global Vaccine Policy & Government Affairs, GSK
Moderator: Maya Chandrasekaran, Presidential Fellow and Program Director, Social Science Research Council
Room 203AB
Apr 2315:40
Conference pass

Defining correlates of protection for ID * Title TBC

Immune Profiling

Senior Representative, Seromyx Systems

Session led by: seromyx-systems
Room 207B
Apr 2315:40
Conference pass

DOC1021 Cell-Based Therapeutic Vaccination as Adjuvant Therapy for MGMT Unmethylated Glioblastoma

Cancer Immunotherapy
William Decker, Professor, Baylor College of Medicine
Room 206
Apr 2315:40
Conference pass

M2SR: NextGen Mucosal Vaccination to Enhance Protection Against Seasonal and Pandemic Influenza

Influenza & Respiratory
Paul Radspinner, CEO, FluGen Inc
Room 202A
Apr 2315:40
Conference pass

The potential of Novavax’s platform technology and Matrix-M™ adjuvant

Partnerships

The safety and tolerability of vaccines adjuvated with Matrix-M

Ruxandra Draghia-Akli, Executive Vice President, Head of Research and Development, Novavax
Room 201
Apr 2315:40
Conference pass

Rapid development of lyophilized VLP-Nucleic acid vaccines – Title TBC

Bioprocessing & Manufacture
Prabuddha Kumar Kundu, Co-founder and MD, Premas Biotech
Room 209AB
Apr 2315:40
Conference pass

Panel: The advantages of running vaccine clinical trials in Australia *Title TBC

Clinical Trials

Senior Representative, 360 Biolabs & additional panelists

Session led by: 360biolabs
Room 208AB
Apr 2315:40
Conference pass

GVDN Case Study - Myocarditis data & GBS Study *TBC

Vaccine Safety
Daniel Salmon, Director, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health
Room 204C
Apr 2315:40
Conference pass

Large-scale production of QS-21 in a continuous growth platform that secures global commercial supply for vaccine adjuvant manufacturing

Supply & Logistics
Jaime Flores-Riveros, CSO, AmerStem
Room 209C
Apr 2315:50
Conference pass

Vaccine manufacturing landscape in Argentina

International Vaccine Bio-clusters
Fernando Lobos, Business Development Director, Sinergium Biotech
Exhibition Stage (Hall D)
Apr 2315:55
Conference pass

AI-designed vaccine based on mRNA technology that protects against a broad range of betacoronaviruses

COVID & Beyond
Kaidre Bendjama, CSO, NEC OncoImmunity AS
Room 207A
Apr 2315:55
Conference pass

A unique next-generation virus-like particle vaccine candidate to protect from EBV-associated diseases

Partnerships

Reserved for Sebastian Goy, COO, EBViously

Sebastian Goy, Chief Operating Officer, EBViously
Room 201
Apr 2316:00
Conference pass

South Africa – Medical Research Council’s public private collaborations

International Vaccine Bio-clusters
Candice Roux, Program Manager: Grants, Innovation and Product Development, South African Medical Research Council
Exhibition Stage (Hall D)
Apr 2316:10
Conference pass

South Korea – Public Private Partnerships in vaccine development across bioclusters in Korea Bloclusters

International Vaccine Bio-clusters
Alice EunJu Lee, Business Development Director, International Vaccine Institute
Kevin Kee-Jong Hong, Professor, KOREA mRNA VACCINE INITIATIVE (KmVAC)
Exhibition Stage (Hall D)
Apr 2316:30
Conference pass

Italy – Fondazione Biotecnopolo: Government collaboration for pandemic preparedness

International Vaccine Bio-clusters
Rino Rappuoli, Scientific Director, Fondazione Biotecnopolo di Siena
Exhibition Stage (Hall D)
Apr 2316:40
Conference pass

Self-amplifying mRNA vaccine – a path from a promising concept to a licensed product

COVID & Beyond
Igor Smolenov, Chief Development Officer, Arcturus Therapeutics
Room 207A
Apr 2316:40
Conference pass

Characterization of vaccine induced immune responses * Title TBC

Immune Profiling
Tyler Sandberg, Product Manager, ELISpot & FluoroSpot, MABTECH
Room 207B
Apr 2316:40
Conference pass

Personalized cancer vaccine pipeline updates & combinations with ADCs *Title TBC

Cancer Immunotherapy
Claudia-Nanette Gann, Vice President Clinical Development, BioNTech
Room 206
Apr 2316:40
Conference pass

A Pandemic Influenza Vaccine and siRNA Therapeutics

Influenza & Respiratory
Michael Breen, Scientist, Tiba Biotech
Justine McPartlan, Scientist, Tiba Biotech
Room 202A
Apr 2316:40
Conference pass

An mRNA vaccine against CMV

Emerging & Re-emerging Diseases
Bishoy Rizkalla, Vice President, Medical Affiars, Latent Virsues, Moderna
Room 202B
Apr 2316:40
Conference pass

Technology showcase: Tech-Driven Triumph: Turbocharging Participant Volume and Data Management

Partnerships
Cheryl Coleman, Chief Executive Officer, Emeritus Research
Paul Bird, Chief Medical Officer, Emeritus Research
Room 201
Apr 2316:40
Conference pass

mRNA Synthesis with improved RNA Polymerases: Prima RNApolsTM for high quality, streamlined and cost-effective mRNA Manufacturing

Bioprocessing & Manufacture
Khaled Yamout, Advisor, Primrose BIo
Room 209AB
Apr 2316:40
Conference pass

Monoclonal Antibody Pre-exposure Prophylaxis for Immunocompromised Patients

Clinical Trials
Session led by: flourish-research
Manish Jain, Principal Investigator, Flourish Research
Room 208AB
Apr 2316:40
Conference pass

Innovation in Enteric Methane Reduction

Veterinary
Caroline Heller, Chief Business Officer, Rumin8
Room 204AB
Apr 2316:40
Conference pass

The growing body of evidence that herpes zoster vaccination has a protective effect for dementia

Vaccine Safety
Pascal Geldsetzer, Assistant Professor of Medicine, Stanford University
Room 204C
Apr 2316:40
Conference pass

Extended session: Beyond efficacy: Moving from innovation to implementation

Vaccine Access

Vaccine efficacy is only one determinant of vaccine impact. This session will explore innovations throughout the development of a novel vaccine which may ensure better access and equity.

  • 4:40 – 4:45pm Introduction:
  • 4.45pm Presentation 1: Establishing large-scale partnerships to address immunization implementation challenges
  • 5.00pm Presentation 2: How can early vaccine, and decision making education generate confidence and higher voluntary uptake in underserved populations?
  • 5.15pm Presentation 3: How do we ensure we are developing vaccines with the greatest value? *Title TBC
  • 5.30pm Presentation 4: Building strong, resilient demand for vaccines
  • 5.45pm Q&A and Discussion:

Litjen (L.J) Tan, Chief Policy and Partnerships Officer, Immunize.org
Birgitte Giersing, Team Lead, Vaccine Prioritization, World Health Organization
Carla Rodriguez-Watson, Director of Research, Reagan Udall Foundation for the F.D.A.
Moderator: Joe Smyser, Chief Executive Officer, PGP (The Public Good Projects)
Room 203AB
Apr 2316:40
Conference pass

Canada: Pandemic capabilities, sustainability plans and 5 new regional hubs

International Vaccine Bio-clusters
Ritu Banerjee, Assistant Deputy Minister, Office of Life Sciences and Biomanufacturing
Exhibition Stage (Hall D)
Apr 2316:55
Conference pass

Unlocking the Future of Vaccine Production: Serum-Free, animal component-free & Suspension Growth Technology

COVID & Beyond
Aziz Cayli, Chief Executive Officer, Florabio A.S.
Room 207A
Apr 2316:55
Conference pass

Assay development and immunogenicity testing for vaccines * Title TBC

Immune Profiling

Reserved, Meso Scale Diagnostics

Room 207B
Apr 2316:55
Conference pass

Technology showcase: Disruptive Technologies and Innovation to Advance Biologics and Biomanufacturing

Partnerships
Lakshmi Krishnan, Vice-President, Life Sciences, National Research Council Canada
Room 201
Apr 2316:55
Conference pass

From Silos to Synergy: How Sponsor, CRO, and Site Collaboration Enhances Product Development – A Case Study

Clinical Trials
Bridget Ristagno, Vice President Clinical Operations, PanAmerican Clinical Research
Sanchia Theron, Executive Director, Business Development, FHI Clinical
Room 208AB
Apr 2316:55
Conference pass

A Double Edged Sword: Obtaining NIH funding to progress a live attenuated canine vaccine into Man

Veterinary
Edward J Robb, Chief Strategy Officer, Anivive Lifesciences
Room 204AB
Apr 2317:00
Conference pass

UK-SEA Vax Hub: Vaccine development in South East Asia – implementing a multi-platform approach

International Vaccine Bio-clusters
Tuck Seng Wong, Director, UK-SEA Vax Hub; Professor of Biomanufacturing, University of Sheffield
Exhibition Stage (Hall D)
Apr 2317:10
Conference pass

Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection

Immune Profiling
Sean Tucker, CSO, Vaxart
Room 207B
Apr 2317:10
Conference pass

Development updates on mRNA4157 *Title TBC

Cancer Immunotherapy
Michelle Brown, Vice President, Portfolio Lead, Oncology, Moderna Therapeutics
Room 206
Apr 2317:10
Conference pass

Innovative Approaches to Accelerate Vaccine Development for Influenza and Beyond

Influenza & Respiratory
Jorge Armero Gimenez, Platform Development Scientist, LenioBio GmbH
Room 202A
Apr 2317:10
Conference pass

Pathogens Prioritization: a scientific framework for epidemic and pandemic research preparedness

Emerging & Re-emerging Diseases
Ana Maria Henao-Restrepo, Co-Lead R&D Blueprint for epidemics, Health Emergencies Programme (WHE),, World Health Organisation
Room 202B
Apr 2317:10
Conference pass

Panel: Private investment – what are VCs looking for before they commit?

Partnerships

Examples of vaccine biotechs striking a successful partnership with emerging markets

John Mattison, Operating Partner, Chief Medical Information Officer, Arsenal Capital Partners
Justin Yang, Advisor, Global Health Investment Corporation
Kabeer Aziz, Partner, Adjuvant Capital
Zeshan Muhammedi, Managing Partner, MBX Capital
David Kaufman, Partner, Third Rock Ventures
Luciana Borio, Venture Partner, A.R.C.H. Venture Partners
Room 201
Apr 2317:10
Conference pass

Sustainable Vaccines Manufacturing: Securing the Future of Global Health

Bioprocessing & Manufacture
Katarina Stenklo, Senior Product Manager, Cytiva
Room 209AB
Apr 2317:10
Conference pass

Presentation TBC – clinical case study

Clinical Trials

Senior Representative, Nucleus Network

Session led by: nucleus-network-pty-ltd
Room 208AB
Apr 2317:10
Conference pass

Panel: Are we doing enough with regards funding safety & behavioral science to foster trust in vaccines? *TBC title

Vaccine Safety
Moderator: Walter Straus, Vice President, Clinical Safety & Risk Management, Moderna Therapeutics
Daniel Salmon, Director, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health
Y. Tony Yang, Professor and Associate Dean, The George Washington University
Amy Pisani, Chief Executive Officer, Vaccinate Your Family
Karen Ernst, Program Director, Voices for Vaccines
Room 204C
Apr 2317:10
Conference pass

Panel: How will thermostable vaccines and new delivery technologies transform our global supply chains?

Supply & Logistics
Joanie Robertson, Program Advisor, PATH
William Falstich, Vice President, Global Supply Chain, Primary Care, Pfizer
Giovanna Riggall, Head of Heath Supply Chain, Unimed
Moderator: Prashant Yadav, Senior Fellow, Council on Foreign Relations
Luciana Maxim, Director, Quality and Impact, VillageReach
Room 209C
Apr 2317:25
Conference pass

COVID & beyond panel: Which vaccination programs with pandemic potential have worked and what else can be done to repurpose COVID facilities and incorporate novel platforms?

COVID & Beyond
Moderator: Rajinder Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers Network
Soleh Ayubi, Deputy Chief Executive Officer, Bio Farma
Rachel Park, Director, EuBiologics Co
Raman Rao, Chief Executive Officer, Hilleman Laboratories Singapore Pte Ltd
Mauricio Zuma Medeiros, Chief Executive Officer, Bio-Manguinhos, Fiocruz
Andrew Wong, Senior Advisor to the Board of Directors, Walvax
Fernando Lobos, Business Development Director, Sinergium Biotech
Room 207A
Apr 2317:25
Conference pass

Panel: Use of AI and other technologies in the prediction of vaccine safety and immunogenicity

Immune Profiling
    li>
  • Convergence of technologies in systems biology gaining traction – metabolomics, proteomics – what have we learnt about signatures of safety and immunogenicity?
  • Why do these results matter clinically?o Collection of clinical data but also correlation of proteomic and metabolomic data with this – what is the experience with this in vaccinology?

Ofer Levy, Director, Precision Vaccines Program, Boston Children's Hospital
Rafick-Pierre Sékaly, Professor and Vice-Chair of Translational Medicine, Emory University - School of Medicine
Ruth Montgomery, Professor, Yale University
Haritha Adhikarla, Senior Translational Immunology Lead, CEPI
Room 207B
Apr 2317:25
Conference pass

Panel: Disease X – how can we be better prepared for the unknown?

Emerging & Re-emerging Diseases
Ruben Rizzi, SVP Global Regulatory Affairs, BioNTech SE
Ana Maria Henao-Restrepo, Co-Lead R&D Blueprint for epidemics, Health Emergencies Programme (WHE),, World Health Organisation
Christian Mandl, CSO, Tiba Biotech
Hamilton Bennett, Sr. Director Vaccine Access and Partnerships, Moderna
Ann-Muriel Steff, Program Lead, CEPI
Moderator: Bassam Hallis, Deputy Director, Vaccine Development & Evaluation Centre, UK Health Security Agency
Room 202B
Apr 2317:25
Conference pass

Clinical case study * Title TBC

Clinical Trials

Senior Representative, Cepheid

Session led by: cepheid
Room 208AB
Apr 2317:25
Conference pass

From research to implementation: commercializing novel technologies in animal health

Veterinary
Mahesh Kumar, Senior VP, Global Biologics R&D, Zoetis
Alan Young, Chief Technology Officer, Medgene Labs
Jonathan E Snyder, Senior Advisor, External Innovation, Elanco
Julia Stephanus, Partner, Borealis Ventures
Moderator: Edward J Robb, Chief Strategy Officer, Anivive Lifesciences
Room 204AB
Apr 2317:40
Conference pass

DNA-based personalized therapeutic cancer vaccines in advanced HCC and GBM

Cancer Immunotherapy
Niranjan Sardesai, President & Chief Executive Officer, Founder, Geneos Therapeutics
Room 206
Apr 2317:40
Conference pass

Universal Influenza Vaccines

Influenza & Respiratory
Ted Ross, Director Global Vaccine Development, Cleveland Clinic
Room 202A
Apr 2317:40
Conference pass

Novel avian substrates for vaccine and vector production

Bioprocessing & Manufacture
Joachim Seipelt, CBO, Nuvonis Technologies GmbH
Room 209AB
Apr 2317:40
Conference pass

Achieving excellence in vaccine trials: The New Zealand advantage * Title TBC

Clinical Trials
Session led by: optimal-clinical-trials-ltd
Room 208AB
Apr 2317:55
Conference pass

QC Testing with GMP Next Generation Sequencing (NGS) for Vaccine Release

Bioprocessing & Manufacture
Stanley Prince, CCO, PathoQuest
Room 209AB
Apr 2317:55
Conference pass

Streamlining decentralized trials *Title TBC

Clinical Trials
Session led by: medable
Room 208AB

Create your personal agenda –check the favourite icon

Apr 249:00
Conference pass

Chair’s opening remarks

COVID & Beyond
Miranda Baxa, Consultant, Health Policy & Insights, Economist Impact
Room 207A
Apr 249:00
Conference pass

Chair's Opening Remarks

Cancer Immunotherapy
Maria Karasarides, Former Vice President, Worldwide Medical Oncology, Early Assets & Biomarkers, The Delphina Group
Room 206
Apr 249:00
Conference pass

Chair's Opening Remarks

Bioprocessing & Manufacture
Irina Ramos, Senior Distinguished Scientist CMC and Innovation, Johnson & Johnson
Room 209AB
Apr 249:00
Conference pass

Chair's Opening Remarks

Clinical Trials
Joan Chambers, Senior Consultant, Tufts Center for the Study of Drug Development, Tufts University Medical School
Room 208AB
Apr 249:00
Conference pass

Chair's Opening Remarks

Veterinary
John El-Attrache, Director of Scientific Services, CEVA santé Animale
Room 204AB
Apr 249:00
Conference pass

Chair's Opening Remarks

Vaccine Safety
Michael Miller, Consultant - Author, HealthPolCom
Room 204C
Apr 249:00
Conference pass

Chair's Opening Remarks

Vaccine Access
Alcir Santos Neto, Manager Health Policy Research, Economist Impact
Room 203AB
Apr 249:10
Conference pass

New proposals for better pandemic preparedness frameworks: Ongoing initiatives and future perspectives

COVID & Beyond
Ruben Rizzi, SVP Global Regulatory Affairs, BioNTech SE
Catherine Hoath, Global Regulatory Strategy Lead, CEPI
Room 207A
Apr 249:10
Conference pass

What are the distinct considerations for immunization in early life?

Immune Profiling
Asimenia Angelidou, Neonatologist, Harvard Medical School
Room 207B
Apr 249:10
Conference pass

How to Make and Share Vaccine-Style Beer

Cancer Immunotherapy

Although early vaccines consisted of crude preparations of live pathogens delivered via oral, intranasal, or intradermal routes, safer modern vaccines tend to use killed pathogens or purified subunits that are injected intramuscularly. There had been a general dogma that oral vaccine delivery can only work with live pathogens, but a recently developed cholera vaccine using orally delivered killed bacteria and a recombinant toxin subunit is highly effective. We hypothesized that a recombinant subunit vaccine targeting the BK polyomavirus (BKV) major capsid protein, VP1, might be immunogenic when administered via oral, nasal, dermal, or rectal routes. Purified BKV VP1 virus-like particles (VLPs) administered intranasally or intradermally elicited average neutralizing antibody titers of roughly 900,000 and 7,500, respectively. Oral and rectal administration of purified VLPs did not induce detectable antibody responses. To test the idea that the immunogenicity of purified VLPs might be degraded by exposure to stomach acid or digestive enzymes, we administered VLPs protected within live brewer’s yeast engineered to express BKV VP1. Mice that ate live yeast mixed with regular mouse chow developed average neutralizing titers above 10,000 - a level that has previously been shown to correlate with resistance to BKV-induced kidney disease in organ transplant patients. The results open the door to the rapid development of vaccine-style beer that can be marketed with structure/function claims along the lines of “supports healthy immune system function,” in compliance with theDietarySupplement Health and Education Act. Plasmids will be shared under OpenMTA.

Chris Buck, Senior Investigator, National Cancer institute
Room 206
Apr 249:10
Conference pass

Expanding RSV Coverage Throughout the Adult Population

Influenza & Respiratory
Iona Munjal, Executive Director, Vaccine Clinical Research and Development, Pfizer
Room 202A
Apr 249:10
Conference pass

Panel: The urgent need for vaccines against mosquito borne diseases

Emerging & Re-emerging Diseases
Moderator: Sushant Sahastrabuddhe, Deputy Director General, International Vaccine Institute
Trevor Wellington, Director, Clinical Trials Center, Walter Reed Army Institute of Research
Juan Carlos Jaramillo, Chief Medical Officer, Valneva Austria GmbH
Gabrielle Breugelmans, Director of Epidemiology and Data Science, CEPI
Room 202B
Apr 249:10
Conference pass

Panel: What kind of partnership mechanisms are necessary to form better strategic collaborations between academic institutes, research institutes, government, biotech and pharma?

Partnerships
Danilo Casimiro, Chief Science Officer, Vaccine R&D, Sanofi
Dan Barouch, Professor Of Medicine, Harvard Medical School
Matthew G. Clark, Joint Project Manager, CBRN Medical, JPEO-CBRND
Moderator: Melinda Hamer, Operating Partner, Global Health Investment Corporation
Room 201
Apr 249:10
Conference pass

BioMaP and BARDA: Ensuring health security and preparedness

Bioprocessing & Manufacture
Nick Stamatakis, President, Meraki Consultants LLC
Room 209AB
Apr 249:10
Conference pass

Decentralized trials for improved speed and retention * Title TBC

Clinical Trials
Session led by: science-37
Tyler Van Horn, VP, Corporate Strategy & Chief of Staff, Science 37
Room 208AB
Apr 249:10
Conference pass

First in class small molecules for aquaculture, companion animal and farm animal health

Veterinary
Thomas Campi, CEO, Modulant Biosciences
Room 204AB
Apr 249:10
Conference pass

Creating healthy information ecosystems

Vaccine Safety
Jessica Malaty Rivera, Science Communication Advisor, PGP (The Public Good Projects)
Room 204C
Apr 249:10
Conference pass

Preventing Medicine Shortages: Strengthening Supply Resiliency and Global Harmonization

Supply & Logistics
Sujatha Narayan, Principal Regulatory Program Director, Genentech
Room 209C
Apr 249:10
Conference pass

Fireside chat: Maximizing access to combination vaccines from review to implementation

Vaccine Access
  • Combination vaccines hold promise for improving respiratory vaccine uptake and maximizing vaccine coverage rates to prevent illness in the United States.
  • This goal can only be achieved if combination vaccines are recommended for use in broad populations and made accessible for providers to purchase and administer.
  • Discussion around how immunization policies and the evolving vaccine landscape can facilitate access to combination vaccines across care settings.
Session led by: avalere-health
Room 203AB
Apr 249:25
Conference pass

Improving Clinical Trial Recruitment * Title TBC

Clinical Trials
William Smith, CEO, AMR
Room 208AB
Apr 249:25
Conference pass

Regionalized Vaccine manufacturing and stockpiling to support routine immunization and outbreak response*title tbc

Supply & Logistics
Luigi Bonfatti, Executive Advisor, RVMC (Regionalized Vaccine Manufacturing Collaborative)
Room 209C
Apr 249:40
Conference pass

Creation of advanced humanized TruHuX mouse to overcome barriers in vaccine & immunology research

Immune Profiling
Paolo Casali, UT Ashbel Smith Professor and Distinguished Prof of Microbiology Immunology & Molecular Genetics, UT Health San Antonio
Room 207B
Apr 249:40
Conference pass

RSV Vaccination for Adults

Influenza & Respiratory
Pilar Snowden, Medical Director, RSV, GSK
Room 202A
Apr 249:40
Conference pass

Monolithic Columns for a High Recovery Purification Process of RNA-LNP Vaccines and Therapeutics

Bioprocessing & Manufacture
Tristan Kovačič, Project Manager, Sartorius BIA Separations
Room 209AB
Apr 249:40
Conference pass

Why you should conduct your next vaccine trial in Africa * Title TBC

Clinical Trials

Senior Representative, p95

Session led by: p95
Room 208AB
Apr 249:40
Conference pass

Title TBC

Veterinary

Senior Representative, Univercells

Room 204AB
Apr 249:40
Conference pass

Gamifying Public Health: Raising Awareness of Infectious Diseases and Immunizations

Vaccine Safety

Reserved

Room 204C
Apr 249:40
Conference pass

VFI open-access adjuvants for Global Health vaccines

Supply & Logistics
Gerben Marsman, Head of Alliance Management, Vaccine Formulation Institute
Room 209C
Apr 249:40
Conference pass

Streamlining adult immunization policies to enhance access and equity

Vaccine Access
Robert Popovian, Chief Science Policy Officer, Global Healthy Living Foundation
Room 203AB
Apr 249:55
Conference pass

COVID-19 vaccine platform updates *Title TBC

COVID & Beyond
Lee-Jah Chang, Head of Clinical Development, Vaccines and Immune Therapies, AstraZeneca
Room 207A
Apr 249:55
Conference pass

mRNA Adjuvants for Prophylactic Vaccines

Influenza & Respiratory
Romain Micol, CEO, Combined Therapeutics
Room 202A
Apr 249:55
Conference pass

Ensuring success throughout the vaccine development lifecycle * Title TBC

Clinical Trials
John Mancini, Vice President, Operations, OrganaBio
Room 208AB
Apr 249:55
Conference pass

Combating Necrotic Enteritis: A Breakthrough with L. reuteri Vectored Antibodies

Veterinary
Arvind Kumar, Vice President of Research, BiomEdit
Room 204AB
Apr 249:55
Conference pass

Never hesitate to educate! A physician's guide for overcoming vaccine hesitancy

Vaccine Safety
Masaru (Rusty) Oshita, MD, QCR Network
Room 204C
Apr 249:55
Conference pass

Panel: How can providers be supported to improve vaccine uptake in Medicaid & underserved areas?

Vaccine Access
  • How are pharmacists delivering VFC to children to improve vaccines?
  • Improving vaccination from community health centers
  • What have we learnt about vaccine access in LTC, billing challenges, etc.
  • How can we help providers afford to keep offering vaccines
  • How do we teach providers about adult immunization?
  • What resources available to providers to improve access and remove barriers to vaccination?
Elizabeth Sobczyk, Associate Executive Director, Post-Acute and Long-Term Care Medical Association (PALTmed)
Lisa Cornbrooks, Senior Director of National Health Campaigns, American Medical Group Association AMGA
Moderator: Robert Popovian, Chief Science Policy Officer, Global Healthy Living Foundation
Carolyn Bridges, Director for Adult Immunization, Immunize.org
Elizabeth Linderbaum, Deputy Director of Regulatory Affairs,, National Association of Community Health Centers Inc
Room 203AB
Apr 2410:10
Conference pass

Live, attenuated Newcastle Disease Virus is a state-of-the-art platform for producing first-in-class mucosal vaccines

COVID & Beyond
Michael Egan, CEO/CSO, CastleVax
Room 207A
Apr 2410:10
Conference pass

Precision immunization for preventing respiratory infections by assessing infection risk and timely nasal vaccination

Immune Profiling

Intramuscularly injected vaccines can induce serum antibodies consisting of monomeric IgG and IgA but not mucosal secretory IgA (sIgA) and therefore are ineffective in preventing infections of SARS-CoV-2 and influenza viruses that invade through upper respiratory tract. It has been recognized that the higher level of nasal spike-specific secretory IgA (sIgA) is correlated with the lower risk of SARS-CoV-2 reinfection. However, mucosal sIgA in the nasal mucosa persists only 6-9 months even after natural infection, afterwards, the risk of re-infection increases. Can a nasal vaccine be designed to mimic a natural infection and induce long-lasting mucosal sIgA? Can the risk of infection be predicted based on assessing the level of nasal sIgA? We propose a precision immunization strategy and illustrate the use of a nasal vaccine with an easy-to-use test strip for the timely usage of nasal vaccination.

Ling Chen, Professor, Guangzhou Medical University,Guangzhou, China
Room 207B
Apr 2410:10
Conference pass

Development of T-cell receptor therapies

Cancer Immunotherapy
Keir Loiacono, Chief Executive Officer, BlueSphere Bio
Room 206
Apr 2410:10
Conference pass

Clesrovimab Clinical (CLEVER and SMART) Program Updates

Influenza & Respiratory
Anushua Sinha, Sr Principal Scientist, Clinical Research, Merck and Co.
Room 202A
Apr 2410:10
Conference pass

Title TBC

Emerging & Re-emerging Diseases

Senior Representative, Emergent BioSolutions

Room 202B
Apr 2410:10
Conference pass

Intranasal Adjuvanted Recombinant Influenza A/H5 Vaccine Induces Broad Priming Against Diverse A/H5N1 Clades in Clinical Trial

Partnerships
Frank Toapanta Yanchapaxi, Associate Professor, University of Maryland
Room 201
Apr 2410:10
Conference pass

Analytical Challenges with Aluminum Adjuvanted Vaccines

Bioprocessing & Manufacture
Elizabeth Joseph, Research Scientist II, Simtra BioPharma Solutions
Room 209AB
Apr 2410:10
Conference pass

Learnings from a 50,000 patient-activated vaccine community

Clinical Trials
Session led by: healthmatch
Room 208AB
Apr 2410:10
Conference pass

Addressing real-world challenges in veterinary vaccinology

Veterinary
Erwin Blomsma, Chief Executive Officer, ViroVet
Room 204AB
Apr 2410:10
Conference pass

Fireside chat: Public health messaging – how can industry and community partners work together to improve the public’s understanding and acceptance of vaccines

Vaccine Safety
Rebecca Martin, Vice President for Global Health, Emory Global Health Institute, Emory University
Moderator: Kashmira Date, Senior Director, Medical & Scientific Affairs (Pipeline Vaccines), Pfizer
Saad Omer, Dean, Peter O’Donnell Jr. School of Public Health, The University of Texas Southwestern Medical Center
Camille (Pope) Campbell, Senior Director, Health Equity, Acclinate
Karen Ernst, Program Director, Voices for Vaccines
Room 204C
Apr 2410:10
Conference pass

Establishing supply for viral vector vaccines in West Africa

Supply & Logistics
Fama Sakho, Global South Fellow from IPD, CEPI
Room 209C
Apr 2410:25
Conference pass

Phase 2b study results that evaluated and compared GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19

COVID & Beyond
Don Diamond, Director, Division of Vaccine Research & Professor, Dept of Hem & HCT, City of Hope Comprehensive Cancer Center
Room 207A
Apr 2410:25
Conference pass

*Title TBC

Bioprocessing & Manufacture
Chase Kempinski, Chief Executive Officer, EVAX Inc.
Room 209AB
Apr 2410:25
Conference pass

CRISPR based approaches for African Swine Fever

Veterinary
Douglas Gladue, Vice President Veterinary Pharmaceutical Development, Seek Labs
Room 204AB
Apr 2410:25
Conference pass

Market Shaping: Demand Health & Market Volatility

Supply & Logistics
Gian Gandhi, Deputy Director, Vaccine Access, Immunization Program Strategy Team, Gates Foundation
Room 209C
Apr 2411:30
Conference pass

Liposome display of recombinant antigens: A versatile approach for coronavirus vaccines

COVID & Beyond

Reserved for Jonathan Lovell, Co-founder, POP Biotechnologies

Room 207A
Apr 2411:30
Conference pass

Panel: Integrated organ immunity – broad mobilization of the immune system for pandemic preparedness

Immune Profiling

- Evidence supporting trained organ immunity- Use as a strategy for imprinting immunity for short periods before conventional vaccines come into play- What are the steps towards translating these findings? – perspectives from industry and regulators- Challenges of translating this into practicality of manufacturing? Manu of ASO1B adjuvant? And live vaccines. 100m of people..

Bali Pulendran, Professor, Department Of Pathology, Microbiology And Immunology, Stanford University School of Medicine (USA)
Margherita Coccia, Director, GSK
Maziar Divangahi, Professor of Medicine, McGill University
Rafick-Pierre Sékaly, Professor and Vice-Chair of Translational Medicine, Emory University - School of Medicine
Room 207B
Apr 2411:30
Conference pass

Panel: Cancer vaccines vs Adoptive T-cell Therapies – what can we learn?

Cancer Immunotherapy
    li>
  • Adoptive T-cell therapies have proved potent for leukemia but not solid tumors - what is missing to infiltrate tumors, what do they not have that cancer vaccines do?
  • Cancer vaccines targeting multiple antigens simultaneously drive t-cell responses more broadly, less likely to drive escape than Adoptive T-cell therapy.
  • Examples of combinations, can cancer vaccines provide “life support” to failing adoptive t-cell therapies by prolonging T-cell persistence?
  • Where should each type of therapy by used

Keir Loiacono, Chief Executive Officer, BlueSphere Bio
Niranjan Sardesai, President & Chief Executive Officer, Founder, Geneos Therapeutics
Kate Rochlin, Chief Operating Officer, IN8bio
Moderator: Wesley Warren, Board Member, Cancer Vaccine Coalition; Executive Director, Translational Research Strategy & Partnerships;, City of Hope
Room 206
Apr 2411:30
Conference pass

Panel: Our global maternal and infant RSV intervention strategies

Influenza & Respiratory
Karen Acker, Assistant Professor of Clinical Pediatrics, Weill Cornell Medicine
Michelle Roberts, Global Medical Franchise Head , RSV, Vaccines, Sanofi
Flor Munoz-Rivas, Associate Professor Of Pediatrics-Infectious Disease, Baylor College of Medicine
Kevin Russell, Associate Vice President, Global Clinical Development, Vaccines, Merck Research Laboratories
Moderator: Phil Krause, Advisor, WHO
Alejandra Gurtman, Sr VP, Vaccines Clinical R, Pfizer
Room 202A
Apr 2411:30
Conference pass

Next Generation Malaria Vaccines: working towards Malaria Elimination

Emerging & Re-emerging Diseases
Adrian Hill, Director and Professor, The Jenner Institute - University of Oxford
Stephen Hoffman, Chief Executive And Scientific Officer, Sanaria
Patrick Duffy, Laboratory Chief, NIAID, NIH
Room 202B
Apr 2411:30
Conference pass

Panel: What happened with the political will to inoculate the world? Funding and support for infectious disease vaccine development

Partnerships
  • What would a new model look like for innovative vaccine development so that we do not rely on reactive funding and resources?
  • Importance of communications and trust – esp. when you have different vaccine options
  • Could we be leveraging “warm places” to support NTDs and tackle local diseases with these distributed plants?
  • How to keep this sustainable even when governments change and during war?
  • How are available resources being used to address gaps in the pipeline or supply chain that are a barrier to access?
James Love, Director, Knowledge Ecology International
Hamilton Bennett, Sr. Director Vaccine Access and Partnerships, Moderna
Luigi Bonfatti, Executive Advisor, RVMC (Regionalized Vaccine Manufacturing Collaborative)
Joe Smyser, Chief Executive Officer, PGP (The Public Good Projects)
Room 201
Apr 2411:30
Conference pass

Case study of IDT Biologika’s iCELLIS 500 platform. A successful scale up for vaccine and CGT manufacturing

Bioprocessing & Manufacture
Martin Pech,  Senior Manager Development & Head of Production CTM, IDT Biologika
Room 209AB
Apr 2411:30
Conference pass

Trends in vaccine research – bringing your next vaccine studies to market

Clinical Trials
Session led by: healthmatch
Room 208AB
Apr 2411:30
Conference pass

Beyond Pet Health Infectious Disease: vaccines and therapeutics

Veterinary
Mayur Patel, VP Global R&D Product Development and Portfolio Management, Elanco
Ashley Kalinauskas, Founder, Torigen Pharmaceuticals
Erwin Blomsma, Chief Executive Officer, ViroVet
Laura Treml, SVP, Companion Animal, Phibro Animal Health Corporation
Moderator: Nicola Mason, Paul A. James and Charles A. Gilmore Endowed Chair Professorship, Professor of Medicine, University of Pennsylvania School of Veterinary Medicine
Room 204AB
Apr 2411:30
Conference pass

Panel: Building trust from the ground up: tackling vaccine education and access from the community level

Vaccine Safety
  • Why are community-level trusted messengers essential in the current climate?
  • As our nation faces a crisis of vaccine confidence, how can we leverage and equip trusted messengers and community-based organizations to increase vaccine education and access, while addressing misinformation?
  • How can we engage community health workers and patient advocates in policy and advocacy efforts?
  • As the healthcare workforce evolves, how can community health workers help ensure the health of their communities and play a role in workforce development?

Moderator: Amy Pisani, Chief Executive Officer, Vaccinate Your Family
Katie Van Tornhout, Founder, Callie Cares
Lecia Imbery, Government Affairs Director, Vaccinate Your Family
Denise Smith, Inaugural Executive Director, National Association of Community Health Workers
Marlen Ramirez, CHW/CHWI, Programs Coordinator, Vaccinate Your Family
Room 204C
Apr 2411:30
Conference pass

A new era for immunization supply chains

Supply & Logistics
Lora Shimp, Director - Immunization Center, John Snow Inc
Gian Gandhi, Deputy Director, Vaccine Access, Immunization Program Strategy Team, Gates Foundation
SOAZIC ELISE WANG SONNE, Economist, World Bank Group
Janeen Madan Keller, Policy Fellow & Deputy Director for Global Health, Center for Global Development - Washington, DC
Room 209C
Apr 2411:30
Conference pass

Panel: How can we tailor digital accessibility tools to the communities that need them?

Vaccine Access
Moderator: Stephen Framil, Corporate Global Head of Accessibility, Merck & Co. Inc.
Monica Goel, President and Co-Founder, Unified Accessibility
Andy Burstein, CEO, Accessible Pharmacy
Sylvia Park-Ekecs, Global Head of Consumer eXperience + Design | CXO | Group SVP, Sanofi
Room 203AB
Apr 2412:00
Conference pass

A platform for developing universal vaccines against Influenza, Covid and other pathogens

COVID & Beyond
Jerald Sadoff, Chief Medical Officer, Centivax
Room 207A
Apr 2412:00
Conference pass

Title TBC

Bioprocessing & Manufacture
Steven Evans, Chief Scientific Officer, NTx
Room 209AB
Apr 2412:15
Conference pass

Preparing to prevent the next pandemic – universal influenza vaccine progress

COVID & Beyond
Roland Zahn, Senior Director, Head Nonclinical and Translational Immunology, Communicable Diseases, J&J Innovative Medicine
Room 207A
Apr 2412:15
Conference pass

Title TBC

Bioprocessing & Manufacture

Senior Representative, Ribopro

Room 209AB
Apr 2413:30
Conference pass

Chair’s opening remarks

Keynotes
Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Keynote Theatre, Hall D
Apr 2413:35
Conference pass

Keynote panel: The role of vaccines in a changing world…priorities, strategies, communications, and behavioral science

Keynotes
  • The public perception of the role of vaccines and their safety
  • How should communication strategies around vaccines take into account cultural, political and religious differences
  • Application of behavioral science to improve vaccine uptake
  • Translating behavioral science insights into improved crisis communication & risk management strategies
Moderator: Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Richard Amlot, Deputy Director, Behavioural Science and Insights, UK Health Security Agency
Alison M Buttenheim Mba, Professor, University of Pennsylvania
Saad Omer, Dean, Peter O’Donnell Jr. School of Public Health, The University of Texas Southwestern Medical Center
Amelia Burke-Garcia, Director, Center for Health Communication Science, NORC at the University of Chicago
Keynote Theatre, Hall D
Apr 2414:35
Conference pass

Keynote closing panel: From bench to bedside – the integration of AI into vaccine research & development

Keynotes
  • Use of AI in the design and validation space
  • Expanding use of AI for pandemic preparedness
  • The impact of the FDA Modernization Act - AI & in silico-based approaches and ability to use human in vitro data to support FDA filings

Moderator: Kati Chilikova, Manager Health Policy Research, Economist Impact
Hans Keirstead, Chairman and CEO, AIVITA Biomedical; CEO, The Human Immunome Project
Jimmy Gollihar, Head of Antibody Discovery and Accelerated Protein Therapeutics (ADAPT), Houston Methodist Hospital
Lovisa Afzelius, Founding CEO and Chair, Apriori Bio; General Partner, Flagship Pioneering
Keynote Theatre, Hall D
Apr 2415:30
Conference pass

Chair Closing Remarks and End of Congress

Keynotes
Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Keynote Theatre, Hall D
last published: 13/Mar/25 11:25 GMT

Follow us

 

 

TICKETS

Our Story

Follow us on X

Join us on LinkedIn

Conference

2025 Speakers

Apply to Speak

Sponsors & Exhibitors

Enquire

Download Prospectus

Register

Venue

Contact us